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ABSTRACT
Liver dysfunction and type 2 diabetes (T2D) are consistently associated. However, it is 
currently unknown whether liver dysfunction contributes to, results from or is merely 
correlated with T2D due to confounding. We used Mendelian randomization (MR) to 
investigate the presence and direction of any causal relation between liver function and T2D 
risk including up to 64,094 T2D cases and 607,012 controls. Several biomarkers were used as 
proxies of liver function [i.e. alanine aminotransferase (ALT), aspartate aminotransferase 
(AST), alkaline phosphatase (ALP), and gamma-glutamyl transferase (GGT)]. Genetic variants 
strongly associated with each liver function marker were used to investigate the effect of liver 
function on T2D risk. In addition, genetic variants strongly associated with T2D risk and with 
fasting insulin were used to investigate the effect of predisposition to T2D and insulin 
resistance, respectively, on liver function. Genetically predicted higher circulating ALT and 
AST were related to increased risk of T2D. There was a modest negative association of 
genetically predicted ALP with T2D risk and no evidence of association between GGT and 
T2D risk. Genetically predisposition to higher fasting insulin, but not to T2D, was related to 
increased circulating ALT.  Since circulating ALT and AST are markers of NAFLD, these 
findings provide some support for insulin resistance resulting in NAFLD, which in turn 
increases T2D risk.
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INTRODUCTION
Observational studies have repeatedly reported that liver dysfunction and type 2 
diabetes (T2D) are associated (1-3). Since the liver plays a core role in the regulation of glucose 
homeostasis, it is hypothesized that liver dysfunction might increase T2D risk by exacerbating 
hepatic insulin resistance, leading to overstimulation of hepatic gluconeogenesis (4). 
Alternatively, it is suggested that insulin resistance and T2D might disturb liver function, 
possibly via an effect of chronic inflammation and immunological changes (5, 6), as well as by 
directly upregulating hepatic lipogenesis (4). It is currently unknown whether liver dysfunction 
contributes to, or results from T2D development, or whether there is a genuine bidirectional 
relationship, where insulin resistance facilitates fat accumulation in the liver, which in turn 
leads to hepatic insulin resistance and increased fasting glucose (7-9). As most evidence to date 
is from observational studies, it is possible that the association between liver dysfunction and 
T2D reflects underlying common causes, such as obesity or lifestyle characteristics.
Plasma concentration of liver enzymes (i.e. alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), alkaline phosphatase (ALP), and gamma-glutamyl transferase 
(GGT)) are routinely measured clinical markers that represent different dimensions of liver 
dysfunction. ALT, located in the cytosol, and AST, located in the mitochondria, are released 
from damaged hepatic cells into the blood after hepatocellular injury or death. ALT and AST 
are potentially useful surrogates for alcohol-induced liver disease and non-alcoholic fatty liver 
disease (NAFLD), defined as hepatic steatosis in the absence of excessive alcohol 
consumption. ALP is present in the ducts of the liver and GGT is located on liver cell 
membranes. The combined elevation of ALP and GGT can indicate obstructive or cholestatic 
liver disease, where bile is not properly transported from the liver because of obstruction of the 
bile duct. GGT is also an indicator of alcohol use (10).
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Classical observational studies show that plasma concentrations of these enzymes, even 
within the normal range, are positively associated with type 2 diabetes (1-3). Mendelian 
randomization (MR), where genetic variants that are strongly associated with a risk factor of 
interest are used to test its causal effect on an outcome, can help to distinguish causal effects 
from associations due to confounding or reverse causality (11, 12). Previous MR studies do not 
support a link between circulating GGT or ALP on T2D risk or glycemic status in Europeans 
(13, 14) or of ALT on T2D risk or glycemic status in Chinese (15). In contrast, MR studies 
reported some evidence of a positive relation of circulating GGT on T2D risk in South Koreans 
(16) and on insulinaemia in Europeans (17) and of circulating ALT on T2D risk in Europeans 
(14). To the best of our knowledge, no MR study has investigated the effect of predisposition 
to T2D or to insulin resistance on liver function markers. 
We have used the largest available datasets to interrogate the potential effect of liver 
dysfunction, proxied by multiple biomarkers (ALT, AST, ALP, and GGT), on T2D risk (64,094 
T2D cases and 607,012 controls), as well as on related outcomes (fasting glucose, insulin and 
lipids). In addition, we have investigated whether predisposition to T2D and insulin resistance 
affect circulating liver function markers (ALT, AST, ALP, and GGT). 
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RESEARCH DESIGN AND METHODS
Study design
We explored the relationship of four liver function markers (plasma concentration of 
ALT, AST, ALP, and GGT) with T2D (primary outcome) and with six related metabolic traits 
(secondary outcomes) reflecting hyperglycemia, assessed by fasting glucose, insulin resistance, 
assessed by fasting insulin, and dyslipidemia, assessed by LDLc, HDLc, total cholesterol, 
triglycerides, using two approaches – multivariable regression and MR. We also used MR to 
investigate whether predisposition to T2D and to insulin resistance are likely to have an impact 
on circulating ALT, AST, ALP, and GGT. The hypotheses, study design and data sources used 
are detailed in Figure 1. 
Data sources
Participant-level data
The UCL-LSHTM-Edinburgh-Bristol (UCLEB) consortium consists of 12 
prospective observational studies comprising over 30,000 participants (18). For the present 
study, data from up to seven UCLEB studies were included in multivariable and MR analyses: 
the British Regional Heart Study (BRHS) (19), British Women’s Heart and Health Study 
(BWHHS) (20), Caerphilly Prospective Study (CaPS) (21), Edinburgh Artery Study (EAS) 
(22), English Longitudinal Study of Ageing (ELSA) (23), Whitehall II study (WHII) (24), 
MRC National Survey of Health and Development (NSHD) (25). Full details of the studies 
included in the UCLEB consortium have been described previously (18). For the multivariable 
analyses of liver marker - T2D associations, we used data from up to 6,593 individuals (728 
T2D cases) from up to five UCLEB studies (BRHS, BWHHS, EAS, CaPS, and NSHD). For 
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the MR analyses of the effect of liver function on T2D risk, we used up to 11,790 individuals 
(1,202 T2D cases) from up to seven UCLEB studies (BRHS, BWHHS, CaPS, EAS, ELSA, 
NSHD, and WHII) where information on genotypes and a liver function marker/s, and/or 
information on genotypes and outcome measure/s were available. 
The Fenland study is a UK population-based study based in the East Cambridgeshire 
and Fenland areas and has been described in detail elsewhere (26). Data from Fenland study 
participants were included in both the multivariable (up to 9,968 individuals) and the MR 
analyses of the liver marker-lipid outcome associations (up to 9,982 individuals) except for 
AST. 
Full details of the exposure, outcome and confounder variables available in each 
UCLEB and Fenland study are given in Supplementary table 1 and participant characteristics, 
in Supplementary tables 2a and 2b.
Summary-level data
For the multivariable analysis, we pooled our individual participant-level results (from 
UCLEB and Fenland studies) with those from two published meta-analysis of the association 
of liver function markers and T2D risk: Kunutsor et al.(2) for ALT and AST (up to 60,359 
participants including 3,890 incident T2D cases) and Fraser et al.(27) for GGT (up to 63,285 
including 2,805 incident T2D cases).
For the MR analysis, we also used publicly available summary level data from genome-
wide association studies (GWAS) for the association of single nucleotide polymorphisms 
(SNPs) with exposures and outcomes from the relevant GWAS studies/consortia. Summary 
statistics for the association between SNP and liver function markers were extracted from 
Chambers et al. (28), including 61,089 individuals with information of ALT, ALP, AST, and 
GGT plasma concentration. Summary data for the association between SNPs and T2D was 
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extracted from a consortium (29) including 62,892 cases and 596,424 controls, mostly of 
European descent. In cases where a liver function SNP could not be found in this latest T2D 
GWAS, data was extracted from a previous T2D GWAS from the DIAGRAM consortium 
including 34,840 cases and 114,981 controls (30). Summary statistics for the association of 
SNPs with fasting glucose and with fasting insulin were obtained from MAGIC (the Meta-
Analyses of Glucose and Insulin-related traits Consortium) consortium (31, 32), which 
included up to 133,010 and 108,557 nondiabetic participants of European ancestry, 
respectively. Summary data for the association of SNPs with LDLc, HDLc, total cholesterol, 
and triglycerides were extracted from the GLGC (Global Lipids Genetics Consortium) 
consortium (33), including 188,577 individuals mostly of European ancestry. We excluded 
Fenland participants who had been included in the meta-analyses of the GLGC consortium to 
avoid having duplicated information from these participants.
Definition of diabetes
In UCLEB studies, T2D definition varied by study and included self-report, medical 
history review, use of glucose lowering medication, or having a fasting glucose value of ≥ 7 
mmol/L(18). For the MR analysis, we used both prevalent and incident cases of type 2 diabetes 
to maximise power, as the prevalent diabetes cases cannot influence genetic variation, which 
is fixed at conception.
In the GWAS, criteria for defining T2D differed across studies and included previous 
diagnosis, fasting glucose ≥ 7 mmol/L, treatment with glucose-lowering medication, or self-
reported T2D status  (29, 30, 34).
Genotyping and quality control
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All studies in UCLEB consortium were genotyped using the Illumina 
CardioMetabochip (Illumina, San Diego, CA, USA). Details on the genotyping and imputation 
quality control criteria used have been previously published (18, 35). Genotyping and 
imputation of missing genotypes in the published GWAS studies used here are described in the 
original publications (28, 30-33, 36, 37). 
Statistical analyses
All continuous variables in the UCLEB and Fenland studies that were not normally 
distributed were natural log transformed. All continuously measured traits were standardised 
within each study to allow comparison between studies. In any published GWAS that did not 
report effects in standard deviation units, effects were standardised based on the GWAS 
reported standard deviation or, where this was not available, the median standard deviation 
across UCLEB studies. 
For analyses involving fasting glucose and fasting insulin we removed individuals with 
type 2 diabetes (defined as a clinical diagnosis, fasting glucose values ≥ 7.0 mmol/L or 
individuals who were taking glucose lowering drugs). We also excluded individuals on lipid 
lowering medication from the multivariable and MR. 
Analyses were performed using Stata/SE version 14.0 (StataCorp, Brownsville, TX) 
and R version 3.4.4 (R Foundation for Statistical Computing, Vienna, Austria). 
Multivariable analysis 
We estimated the association between each liver function marker and T2D in each 
UCLEB study using logistic regression. For continuous outcomes we used linear regression 
models. We adjusted the logistic/linear regression models for age, sex (if relevant), and for as 
many potential confounders available in each study from the following: BMI, waist 
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circumference, alcohol consumption, smoking, and social class. We then used 
DerSimonian and Laird random-effects model meta-analysis to combine these estimates with 
results from the published meta-analyses of Kunutsor et al (2) and Fraser et al (27) for the 
associations between ALT, AST and GGT with T2D, excluding any UCLEB studies that had 
contributed to the published meta-analyses. In the previously published meta-analyses, all (27) 
or some (2) of the participating studies expressed T2D results as hazard ratios. Given the overall 
proportion of T2D cases was lower than 10%, hazard ratios and odds ratios were assumed to 
approximate to the same measure of T2D relative risk in our meta-analysis. 
Mendelian randomization analysis 
For the MR analysis, we used multiple genetic variants robustly associated with 
circulating ALT, AST, ALP, or GGT as genetic instruments for each liver function marker to 
investigate their effect on T2D and other outcomes. We also applied MR analysis to assess the 
effect of predisposition to T2D and fasting insulin (a marker of insulin resistance) on 
circulating ALT, AST, ALP, or GGT by using genetic variants robustly associated with T2D 
risk and fasting insulin. We used a “two-sample” analysis strategy in which the genetic variant-
exposure and genetic variant-outcome associations are estimated from different data sources 
with comparable populations (38). 
Selection of genetic instruments for liver function markers
Genetic instruments for each liver function marker were defined as independent SNPs 
(R2 < 0.3) associated with each liver function marker at genome-wide levels of significance 
(P < 5 x10-8) from GWAS in the NIHR GWAS catalogue (available at 
www.ebi.ac.uk/gwas/home, last accessed on July 2017). At the time the study was conducted, 
there was limited GWAS data available for AST. Therefore, we conducted a genome-wide 
association analysis in up to 6,647 individuals from five UCLEB studies (BRHS, BWHHS, 
CaPS, EAS, and ET2DS) to identify novel variants for AST, as this biomarker had only been 
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assessed in one previous GWAS with fewer than 1,000 individuals (37). We selected GWAS 
studies, which had been primarily conducted in populations of European ancestry. In total, we 
selected 4, 3 (including the two novel SNPs identified from our own GWAS), 15, and 26 
independent SNPs associated with ALT, AST, ALP, and GGT, respectively (Supplementary 
table 3). UCLEB data were excluded from the MR analysis of AST (as an exposure) to avoid 
any bias from Winner’s curse (39).
Selection of genetic instrument for type 2 diabetes and fasting insulin
We used multiple independent SNPs strongly associated (P < 5 x10-8) with T2D risk (n 
= 139 SNPs) (29) and with fasting insulin (n = 14 SNPs) (32). T2D SNPs were identified as 
reported by the original GWAS publication (29). Fasting insulin SNPs were selected from data 
published by Scott et al (32) using the R package ‘TwoSampleMR’ excluding any correlated 
SNPs (R2 > 0.001) (40).
Main analysis 
In the main Mendelian randomization analyses, we used the conventional inverse 
variance weighted (IVW) estimator. The IVW method consists of a weighted regression of the 
SNP-outcome regression coefficients on the SNP-exposure regression coefficients constraining 
the intercept to be zero. IVW weights are the inverse of the variance of the SNP-outcome 
regression coefficients. For a dichotomous outcome such as a T2D status, the regression 
coefficient of the SNP-outcome association is a log odds ratio from a logistic regression model. 
The resulting regression coefficient from the IVW regression represents an increase/decrease 
in the outcome per unit increase in the exposure. 
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Sensitivity analyses
We performed several sensitivity analyses to test whether the MR IVW estimates are 
likely to be biased by unbalanced horizontal pleiotropic effects (i.e. due to genetic variants that 
affect the outcome independently of the exposure of interest). We used MR-Egger regression 
method (41) and the weighted median estimator (42), both of which are more robust to 
pleiotropic genetic variants, to test the extent to which any unbalanced pleiotropy may have 
biased the IVW result. The MR-Egger method is similar to the IVW except that the model 
allows the intercept to vary. The intercept of the MR-Egger regression will reflect the average 
pleiotropic effect across genetic variants  and the slope coefficient will provide an estimate of 
the causal effect provided that the InSIDE (Instrument Strength Independent of Direct Effect) 
assumption holds, which requires that there is no correlation between SNP-exposure 
association and any direct (pleiotropic) effects of SNP on outcome (41). In contrast, the 
weighted median estimator gives consistent estimates even if up to 50% of weight in the 
analysis comes from invalid genetic instruments (42). For the MR analysis of the effect of 
insulin resistance, proxied by fasting insulin, on liver markers, we have performed an additional 
sensitivity analysis, in which we used multivariable MR (43) to adjust results by BMI (32). In 
all analyses with GWAS data, we have excluded SNPs with C/G or A/T genotypes and minor 
allele frequency > 0.42 due to ambiguity problems they could introduce when harmonising 
SNP-exposure and SNP-outcome datasets (44).
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RESULTS
Genetic instruments for liver function markers, T2D risk and fasting insulin 
Results for the association of genetic instruments with the respective liver function 
marker are given in Table 1. Most of the genetic instruments previously identified in GWAS 
consortia replicated (had consistent direction and magnitude) in UCLEB and Fenland, seven 
were not available in UCLEB but were replicated in Fenland, seven were null or in the opposite 
direction in UCLEB but consistent in Fenland, and one was null in Fenland (but consistent in 
UCLEB). In all cases, confidence intervals in UCLEB and Fenland included the point estimate 
from the published GWAS.
For the known variant for AST (rs17109512), only P-values were provided by the 
original GWAS and, therefore, it was not possible to compare effect estimates with that from 
the previous GWAS. The two novel variants for AST, identified in our GWAS conducted in 
five UCLEB studies, were replicated in independent data sources (Table 1 and Supplementary 
table 4). When meta-analysing UCLEB and Fenland studies, 4, 13 and 22 variants were 
replicated from 4, 15 and 26 variants associated with ALT, ALP and GGT, and the remaining 
variants were directionally consistent with the previous reports (data only shown for UCLEB 
and Fenland separately). 
Results for the association of the 139 T2D genetic instruments with T2D risk are given 
in Supplementary table 5. Results for the association of the 14 fasting insulin genetic 
instruments with fasting insulin (in SD log pmol/L) are given in Supplementary table 6.  
Association of genetic variants related to liver function markers with potential confounders 
of the exposure-outcome association
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Some individual SNPs used as instruments in the MR analysis were associated with 
potential confounders of the exposure-outcome association (e.g. age, BMI, waist 
circumference, waist-hip ratio, and other liver function markers). However, when combined 
into a single instrument using fixed-effect meta-analysis, there was no strong evidence that 
genetic instruments were associated with potential confounders, except for the ALT instrument 
that was also associated with AST and GGT, and the AST instrument that was associated with 
ALT (Supplementary tables 7a and 7b). 
Multivariable analysis between liver function markers and T2D and related continuous 
outcomes  
Pooled results from multivariable analyses across the relevant UCLEB and Fenland 
studies and published meta-analyses are given in Figure 2A. Most liver function markers were 
positively associated with T2D risk. The OR for T2D was 1.27 [95% CI: 1.15, 1.40] for ALT, 
1.06 [95% CI: 0.97, 1.17] for AST, 1.25 [95% CI: 1.10, 1.43] for ALP and 1.61 [95% CI: 1.15, 
2.26] for GGT (per standard unit increase in the liver function marker). Heterogeneity across 
studies was low for ALT and ALP (I2 = 0%) but high for AST (I2 = 81%) and GGT (I2 = 93%) 
(Figure 2A). 
In meta-analyses of the continuous outcomes, ALT was positively associated with 
insulin and triglycerides. AST was positively associated with insulin and HDLc. ALP was 
negatively related with HDLc. GGT was positively associated with all continuous outcomes 
(Supplementary table 8). 
Effect of liver function markers on T2D and related continuous outcomes using MR 
Pooled results from the MR across UCLEB, Fenland and GWAS studies are given in 
Figure 2A and Supplementary table 8. In the main MR analysis (IVW), the OR for T2D was 
Page 16 of 54
For Peer Review Only
Diabetes
1.45 [95% CI: 1.10, 1.92] for ALT, 1.25 [95% CI: 1.14, 1.38] for AST, 0.91 [95% CI: 0.86, 
0.97] for ALP and 0.92 [95% CI: 0.80, 1.06] for GGT (per each standard unit increase in the 
liver function marker) (Figure 2A). The other MR methods (MR-Egger and weighted median) 
used as sensitivity analyses were consistent with IVW estimates for ALT, AST and ALP. The 
inverse point estimate for the IVW association between GGT and T2D changed in direction 
when using the MR-Egger method. There was no clear evidence of unbalanced horizontal 
pleiotropy in any liver function marker – T2D associations based on the intercept for MR-
Egger method (all P-values ≥0.38). Heterogeneity between UCLEB and GWAS estimates was 
low for all liver markers. For AST, only GWAS data were available for analysis (Figure 2A).
In meta-analyses of the continuous outcomes, there was some evidence across different 
MR methods that genetically predicted AST and ALP were negatively related to HDLc, LDLc 
and total cholesterol (Supplementary table 8). There was some evidence of unbalanced 
horizontal pleiotropy of ALT instruments in relation to HDLc, LDLc, total cholesterol and 
triglycerides (Supplementary table 9). 
Effect of T2D and insulin resistance on liver function markers using MR 
Overall, findings from MR analysis did not consistently support a reverse causal effect 
of T2D on any of the liver function markers assessed (ALT, AST, ALP, or GGT). In the main 
MR analysis (IVW), higher predisposition to T2D (each increase in 1 log odds) was related to 
an increase of 0.06 SD units of ALT [95% CI: 0.02, 0.09], but not of AST [0.01; 95% CI: -
0.04, 0.07], ALP [-0.04; 95% CI: -0.11, 0.02] or GGT [0.03; 95% CI: -0.01, 0.06]. Results for 
ALT were substantially attenuated when using MR methods that are more robust to pleiotropic 
variants: 0.01 [95% CI: -0.06, 0.08] for MR-Egger and 0.03 [95% CI: -0.02, 0.07] for the 
weighted median estimator (Figure 2B). 
On the other hand, there was evidence from the main MR findings that higher insulin 
resistance, proxied by fasting insulin, increases circulating ALT. Results were consistent with 
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the weighted median and BMI-adjusted estimates. MR-Egger point estimates substantially 
differed, but 95% CI were very wide. Results for the other liver markers were less consistent 
across different MR methods and 95% CI were wide (Table 2). 
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DISCUSSION
More than a century ago a link between liver disease and diabetes was described (45). 
Since then, multiple observational studies have repeatedly reported that liver dysfunction and 
T2D are associated (1-3), as broadly replicated by our multivariable analysis using clinical 
biomarkers (i.e. circulating ALT, AST, ALP, and GGT) as proxies of liver dysfunction. 
Nevertheless, it is still unclear whether this association reflects causation, and if so, whether 
liver dysfunction represents a cause or a consequence of T2D. 
Our study expands on previous MR analyses investigating the effect of liver 
dysfunction on T2D risk by including a more comprehensive set of liver function markers 
routinely used in clinical practise in the largest available datasets and by applying bi-directional 
MR to investigate whether predisposition to T2D and to insulin resistance might instead lead 
to liver dysfunction. 
Our findings from the MR analyses show evidence that genetic predisposition to higher 
circulating ALT and AST is related to higher risk of T2D. No strong evidence of a causal effect 
of genetically predicted GGT on T2D, and evidence of a modest negative effect of genetically 
predicted ALP on T2D were found. Genetic predisposition to T2D did not appear to influence 
blood concentration of any of the studied liver function markers (ALT, AST, ALP, and GGT), 
whereas genetic predisposition to insulin resistance, proxied by fasting insulin, seems to 
increase ALT (effects on other liver markers are uncertain).
Our results are broadly consistent with two previous MR studies, of largely European 
origin participants (using a study sample that partially overlaps with ours), which reported 
strong evidence for a positive effect of ALT on T2D (14), but not for ALP (14) or GGT (13, 
14). Results for ALP (14) were directionally consistent with our findings, but we were better 
powered to test for the association between ALP and T2D risk given the substantially larger 
number of T2D cases and controls included in our analyses. In non-European populations, MR 
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studies suggest that ALT does not relate to T2D risk in Chinese adults (15), but that higher 
GGT increases T2D risk in Koreans (16). However, the latter result might be explained by 
statistical overfitting since instruments were selected from a GWAS that included the 
population used in the MR analyses (~ 20% of the GWAS discovery sample). 
The different liver biomarkers reflect different aspects of liver dysfunction. High 
circulating ALT and AST are widely used proxies of NAFLD, while high circulating ALP and 
GGT (in combination) are more related to obstructive or cholestatic liver disease. The positive 
association between genetically predicted liver function markers and T2D in MR analyses was 
robust for ALT and AST, but not apparent for ALP or GGT, which suggests that NAFLD might 
be the primary type of liver dysfunction driving these associations. 
In agreement with that, a genetic variant (rs738409) in perfect linkage disequilibrium 
(R2 = 1.0 for 1000 Genomes European population - GRCh37) with one of our instruments for 
AST (rs738408) has been previously reported to be associated with computed tomography 
(CT) measured hepatic steatosis (46, 47). NAFLD is the most common cause of chronic liver 
disease in Western countries owing to the rapid increase in obesity prevalence (48, 49). 
NAFLD affects 70% of patients with type 2 diabetes (T2D) in contrast to around 20% of the 
general population (48, 49). 
To our knowledge previous MR studies have not examined the causal effect of 
predisposition to T2D or insulin resistance on liver dysfunction. We found supportive evidence 
that insulin resistance increases circulating ALT. Our combined findings that insulin resistance 
(but not T2D) may cause elevated ALT (marker of NAFLD), and that ALT and AST are in 
turn related to increased T2D risk (but not insulin resistance) are consistent with the twin-cycle 
hypothesis (8), which postulates that there is a vicious cycle between hepatic insulin resistance 
and β cell dysfunction. According to the twin-cycle hypothesis, elevated insulin (due to insulin 
resistance) stimulates de novo lipogenesis in the liver, which promotes hepatic insulin 
resistance leading to overstimulation of hepatic gluconeogenesis and increased fasting glucose. 
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The resulting increased output of triglycerides and glucose by the liver to the circulation would 
impair beta cell function, eventually leading to type 2 diabetes (9). 
On the other hand, it is worth emphasising that the relation between ALT/AST and T2D 
risk might be explained by factors other than NAFLD since circulating ALT/AST are not 
specific markers of NAFLD and can also increase in response to liver injury from other causes, 
such as drug toxicity, infection and alcohol consumption (50, 51). In addition, there is some 
evidence that hepatic triglyceride accumulation by itself may not necessarily cause metabolic 
changes increasing the risk of cardiometabolic complications (52) and that there might be 
multiple T2D subtypes that differ in terms of disease presentation and responsiveness to 
interventions (53), which we were unable to tease out due to the predominant use of summary 
level data. Finally, given the key roles of ALT and AST in the intermediary metabolism of 
glucose and amino acids, we cannot fully discard that they might be directly implicated in T2D 
development. 
Although MR can substantially improve causal inference in Epidemiological studies 
(54), it is important to note that the reliability of MR findings depend on the three core 
assumptions of instrumental variable (IV) analysis, which require that genetic instruments are 
strongly associated with the exposure (IV1), are not related to exposure-outcome confounders 
(IV2) and only influence the outcome through the exposure (IV3). 
To avoid violations of IV1, we have selected genetic variants strongly associated with 
liver function markers (P < 5*10-8), that broadly replicated in independent datasets. It should 
also be noted that our genetic instruments were selected to be strongly associated with each 
liver function marker in the largest available GWAS (P < 5*10-8) and that some variants 
relevant to specific forms of liver dysfunction might not have met our inclusion criteria, as is 
the case of variants nearby TM6SF2, previously reported to be associated with NAFLD in a 
GWAS (55) and with alcohol-related cirrhosis in an exome-wide association study (56). To 
minimise the risk of population stratification, which could violate IV2, we mostly restricted 
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our analyses to individuals of European ancestry. IV3 could be violated in the presence of 
horizontal pleiotropy. We have attempted to address that by examining the relation of the 
genetic variants with several social, behavioural and metabolic phenotypes and by using 
methods that are more robust to violations of this assumption in sensitivity analyses (i.e. MR-
Egger and weighted median estimator). Overall, there was no strong suggestion that horizontal 
pleiotropy could have biased our results. Importantly, our liver function instruments were not 
associated with general adiposity measures such as BMI, and therefore it is unlikely that these 
associations are driven by general adiposity. However, it is important to note that we cannot 
fully discard that our genetic instruments may be associated with exposure-outcome 
confounders that we have not tested for and that the sensitivity analyses used (i.e. MR-Egger 
and weighted median) are of limited use for exposures instrumented by few genetic variants 
(as in the analyses of ALT and AST as exposures). 
Two-sample MR makes the additional assumption that data from two independent (but 
comparable) populations are used. In our study, there was some overlap between participants 
used to estimate SNP-exposure and SNP-outcome associations. However, this is unlikely to 
bias the study results since the overlap is very low in proportion to the overall sample size (< 
7% of T2D cases in the main analysis) (57).
Finally, effect estimates for the relation of each liver function marker on T2D risk 
should be interpreted with caution given these biomarkers are unlikely to be the causal factors 
for T2D risk, but rather proxies of liver function.
In conclusion, MR findings indicate that increased circulating ALT and AST is related 
with higher T2D risk, while increased circulating ALP is associated with lower T2D risk. In 
addition, higher fasting insulin (but not predisposition to T2D) is related to higher circulating 
ALT. Since circulating ALT and AST are markers of NAFLD, these findings provide some 
support for insulin resistance resulting in NAFLD, which in turn increases T2D risk.
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Table 1. The associations of individual SNPs (used as genetic instruments in Mendelian randomization analyses) with the relevant liver function 
markers in UCLEB, Fenland and GWAS studies  
SNP
Liver 
function 
marker
Locus*
Effect size in SD 
units in UCLEB 
studies† (95% CI)
Effect size in SD 
units in Fenland 
study† (95% CI)
Effect size in SD units 
from published 
GWAS‡ (95% CI)
rs6834314 ALT HSD17B13, MAPK10 0.05 (0.01, 0.09) 0.05 (0.02, 0.07) 0.06 (0.04, 0.08)
rs11597390 ALT CPN1 0.09 (0.05, 0.13) 0.03 (0.01, 0.06) 0.04 (0.03, 0.06)
rs2143571 ALT SAMM50 0.14 (0.09, 0.19) 0.07 (0.04, 0.12) 0.09 (0.07, 0.11)
rs2954021 ALT TRIB1n 0.03 (-0.01, 0.07) 0.02 (-0.00, 0.04) 0.04 (0.02, 0.05)
rs17109512 AST GOT1 -0.04 (-0.18, 0.11) N/A 0.03 (-0.05, 0.1)
rs738407 AST PNPLA3 0.13 (0.08, 0.19) N/A 0.09 (0.06, 0.12)
rs738408 AST PNPLA3 0.12 (0.08, 0.17) N/A 0.19 (0.16, 0.22)
rs1780324 ALP NBPF3-ALPL 0.07 (0.02, 0.12) 0.08 (0.05, 0.10) 0.09 (0.07, 0.11)
rs16856332 ALP ABCB11 -0.02 (-0.20, 0.15) 0.06 (-0.01, 0.13) 0.14 (0.09, 0.19)
rs9467160 ALP GPLD1 0.06 (0.01, 0.12) 0.10 (0.07, 0.13) 0.1 (0.08, 0.13)
rs514708 ALP ABO 0.06 (0.00, 0.12) 0.08 (0.05, 0.11) 0.1 (0.08, 0.13)
rs2236653 ALP ST3GAL4 0.01 (-0.05, 0.07) 0.07 (0.04, 0.10) 0.06 (0.04, 0.08)
rs7186908 ALP HPR, PMFBP1 -0.02 (-0.09, 0.05) 0.02 (-0.01, 0.05) 0.07 (0.05, 0.1)
rs7267979 ALP ABHD12, GINS1, PYGB 0.03 (-0.02, 0.08) 0.07 (0.04, 0.10) 0.05 (0.03, 0.07)
rs281377 ALP ABO 0.00 (-0.05, 0.06) 0.06 (0.04, 0.09) 0.07 (0.05, 0.09)
rs314253 ALP ASGR1o, DLG4n 0.02 (-0.04, 0.07) 0.04 (0.01, 0.07) 0.08 (0.06, 0.1)
rs579459 ALP ABO 0.08 (0.02, 0.14) 0.25 (0.22, 0.28) 0.31 (0.28, 0.34)
rs6984305 ALP PPP1R3B -0.03 (-0.11, 0.05) 0.08 (0.04, 0.12) 0.1 (0.07, 0.13)
rs7923609 ALP JMJD1Cnce, NRBF2e 0.05 (0.00, 0.10) 0.09 (0.06, 0.11) 0.08 (0.06, 0.1)
rs174601 ALP C11orf10e, FADS1e, FADS2ne -0.00 (-0.06, 0.05) 0.06 (0.03, 0.08) 0.06 (0.04, 0.09)
rs2954021 ALP TRIB1 0.07 (0.01, 0.12) 0.04 (0.01, 0.06) 0.05 (0.03, 0.07)
rs10819937 ALP ALDOBo, C9orf125n Not in UCLEB 0.06 (0.02, 0.09) 0.09 (0.06, 0.12)
rs1497406 GGT RSG1, EPHA2 0.05 (0.01, 0.09) 0.07 (0.04, 0.09) 0.06 (0.04, 0.07)
rs12145922 GGT CCBL2, PKN2 -0.02 (-0.05, 0.02) 0.01 (-0.02, 0.03) 0.04 (0.03, 0.06)
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rs1335645 GGT CEPT1, DENND2D Not in UCLEB 0.03 (-0.01, 0.07) 0.07 (0.04, 0.09)
rs10908458 GGT DPM3, EFNA1, PKLR 0.04 (0.01, 0.07) 0.05 (0.02, 0.07) 0.06 (0.04, 0.07)
rs13030978 GGT MYO1B, STAT4 0.07 (0.02, 0.12) 0.03 (0.01, 0.06) 0.06 (0.04, 0.08)
rs2140773 GGT EFHD1, LOC100129166 -0.01 (-0.04, 0.03) 0.02 (-0.01, 0.04) 0.05 (0.03, 0.06)
rs4547811 GGT ZNF827 0.08 (0.03, 0.13) 0.09 (0.06, 0.12) 0.1 (0.08, 0.12)
rs4074793 GGT ITGA1 0.14 (0.07, 0.20) 0.07 (0.02,0.11) 0.08 (0.05, 0.12)
rs9296736 GGT MLIP 0.03 (0.00, 0.07) 0.04 (0.02, 0.07) 0.05 (0.03, 0.06)
rs754466 GGT DLG5 Not in UCLEB 0.07 (0.04, 0.10) 0.05 (0.03, 0.07)
rs8038465 GGT NPTN -CD276 0.04 (-0.00, 0.09) 0.00 (-0.02, 0.03) 0.04 (0.02, 0.05)
rs4581712 GGT DYNLRB2 0.09 (-0.00, 0.18) 0.07 (0.04, 0.10) 0.05 (0.03, 0.07)
rs1076540 GGT MICAL3 0.05 (0.01, 0.09) 0.06 (0.03, 0.09) 0.07 (0.06, 0.09)
rs2739330 GGT DDT, DDTL, GSTT1, GSTT2BMIF 0.06 (0.02, 0.10) 0.03 (0.01, 0.06) 0.06 (0.04, 0.08)
rs4820599 GGT GGT1 0.13 (0.10, 0.17) 0.09 (0.06, 0.12) 0.13 (0.11, 0.15)
rs10513686 GGT SLC2A2nc 0.06 (0.01, 0.11) 0.04 (0.01, 0.08) 0.08 (0.05, 0.1)
rs1260326 GGT C2orf16e, GCKRnc 0.03 (-0.00, 0.06) 0.05 (0.02, 0.07) 0.05 (0.03, 0.07)
rs17145750 GGT MLXIPLnce 0.08 (0.03, 0.12) 0.07 (0.03, 0.10) 0.07 (0.04, 0.1)
rs339969 GGT RORAn 0.05 (0.02, 0.09) 0.05 (0.03, 0.08) 0.07 (0.05, 0.09)
rs516246 GGT FUT2 0.04 (0.01, 0.07) 0.04 (0.01, 0.06) 0.04 (0.02, 0.05)
rs7310409 GGT HNF1Anc, C12orf27e 0.11 (0.08, 0.15) 0.10 (0.08, 0.13) 0.1 (0.09, 0.12)
rs944002 GGT C14orf73nc 0.12 (0.08, 0.15) 0.09 (0.06, 0.12) 0.1 (0.08, 0.12)
rs6888304 GGT CDH6n Not in UCLEB 0.05 (0.02, 0.08) 0.04 (0.02, 0.06)
rs9913711 GGT FLJ37644e, SOX9n Not in UCLEB 0.05 (0.03, 0.08) 0.04 (0.02, 0.05)
rs12968116 GGT ATP8B1ncg Not in UCLEB 0.05 (0.01, 0.09) 0.07 (0.04, 0.1)
rs4503880 GGT NEDD4Ln Not in UCLEB 0.07 (0.04, 0.10) 0.06 (0.03, 0.08)
* Mapped gene for each SNP is given as reported in the original GWAS publication.
† All SNP-liver function marker associations in the UCLEB studies and the Fenland study were adjusted for age and sex (if relevant). Individual study 
estimates in UCLEB were combined using fixed effect meta-analyses. 
‡ Effect sizes extracted from Chambers et al., 2011 (28). GWAS effect sizes for ALT, ALP and GGT were converted to SD units using the median SD 
from the UCLEB and Fenland studies. 
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ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma-glutamyl transferase; GWAS: genome-
wide association study; N/A: not applicable; SNP: single nucleotide polymorphism; SD: standard deviation; UCLEB consortium: UCL-LSHTM-
Edinburgh-Bristol consortium
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Table 2. Mendelian randomization analysis of the effect of insulin resistance (proxied by 
circulating fasting insulin) on liver function markers
Outcome Method Beta 95%CI P-value
IVW 0.46 0.22; 0.69 0.0001
MR Egger 0.14 -1.15; 1.42 0.84
Weighted median 0.43 0.10; 0.76 0.01ALT
IVW adjusted by BMI 0.47 0.21; 0.72 0.0004
IVW 0.31 -0.1; 0.71 0.14
MR Egger -1.01 -3.31; 1.29 0.41
Weighted median 0.32 -0.26; 0.89 0.28AST
IVW adjusted by BMI 0.25 -0.22; 0.72 0.30
IVW -0.14 -0.78; 0.49 0.66
MR Egger 3.39 0.37; 6.41 0.05
Weighted median -0.40 -0.88; 0.07 0.09ALP
IVW adjusted by BMI -0.21 -0.6; 0.18 0.29
IVW 0.28 -0.24; 0.8 0.3
MR Egger -2.35 -4.95; 0.25 0.10
Weighted median 0.51 0.18; 0.84 0.003GGT
IVW adjusted by BMI 0.22 -0.1; 0.54 0.18
Results correspond to mean difference (in S.D. units) of log10 liver function marker (95% 
CI) per one S.D increase in fasting insulin (in pmol/L). ALT: alanine aminotransferase; 
AST: aspartate aminotransferase; ALP: alkaline phosphatase; GGT: gamma-glutamyl 
transferase; IVW: inverse variance weighted method; S.D.: standard deviation.
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Figure legends
Figure 1. Study design and data sources used to investigate the effect of liver dysfunction 
(proxied by biomarkers: ALT, AST, ALP, and GGT) on type 2 diabetes or secondary outcomes 
(fasting glucose, fasting insulin, LDL-C, HDL-C, total cholesterol, and triglycerides) (A) and 
the effect of predisposition to type 2 diabetes or insulin resistance on circulating liver function 
biomarkers (B)
As shown in figure 1A, the multivariable association of liver function markers with T2D risk (or related outcomes) 
was estimated by meta-analysing results from each data source using logistic regression models (or linear 
regression models in the case of secondary outcomes) with participant-level data from relevant studies within 
UCLEB consortium (BRHS, BWHHS, MRC-NHSD) and summary-level data from the published meta-analyses 
of Kunutsor et al (2013) and Fraser et al (2009). We also estimated the association of liver function markers with 
T2D risk (or secondary outcomes) using a Mendelian randomization approach. In Mendelian randomization 
analysis, we used different data sources to estimate the SNP-liver function marker association (UCLEB consortium 
— BRHS, BWHHS and MRC-NHSD —, Fenland study, and GWAS of liver function markers — Chambers et al 
(2011)) —, and SNP-T2D risk association (UCLEB — BRHS, BWHS, CaPS, EAS, ELSA, MRC-NHSD, and 
WHII —, and GWAS consortium) or SNP-secondary outcomes. As shown in figure 1B, the summary-level data 
for the association of SNP-T2D risk and SNP-fasting insulin for the reverse MR was extracted from GWAS 
consortia, and the association of SNP-liver function marker was extracted from Chambers et al (2011). ALP: 
alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; BMI: body mass index;  
BRHS: British Regional Heart Study; BWHHS: British Women’s Heart and Health Study; CaPS: Caerphilly 
Prospective Study; DIAGRAM consortium:  Diabetes Genetics Replication And Meta-analysis consortium; EAS: 
Edinburgh Artery Study; ELSA: English Longitudinal Study of Ageing; GGT: gamma-glutamyl transferase; 
GWAS: genome-wide association study; HDL-C: high density lipoprotein-cholesterol; LDL-C: low density 
lipoprotein-cholesterol; MRC-NSHD: National Survey of Health and Development; SNPs: single nucleotide 
polymorphisms; T2D: type 2 diabetes; UCLEB consortium: UCL-LSHTM-Edinburgh-Bristol consortium; WHII: 
Whitehall II study.
Figure 2. Multivariable and Mendelian randomization analysis of the effect of liver 
function on T2D (A) and Mendelian randomization analysis of the effect of T2D on liver 
function markers (B). 
Results from Figure 1A correspond to odds ratio of T2D per unit increase in standardized liver function 
markers (and 95% confidence interval). Results from Figure 1B correspond to change in standardized liver 
function markers per unit increase in log odds of T2D (and 95% confidence interval). I-squared indicates 
between-study heterogeneity and is only presented when estimates for more than one study were available. 
ALT: alanine aminotransferase; AST: aspartate aminotransferase; ALP: alkaline phosphatase; GGT: 
gamma-glutamyl transferase; SNPs: single nucleotide polymorphisms; T2D: type 2 diabetes.
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Figure 1. Study design and data sources used to investigate the effect of liver dysfunction (proxied by biomarkers: ALT, AST, ALP, and GGT) on type 2 diabetes or 
secondary outcomes (fasting glucose, fasting insulin, LDL-C, HDL-C, total cholesterol, and triglycerides) (Figure 1A) and the effect of predisposition to type 2 diabetes or 
insulin resistance on circulating liver function biomarkers (Figure 1B)
As shown in figure 1A, the multivariable association of liver function markers with T2D risk (or related outcomes) was estimated by meta-analysing results from each data source using logistic regression 
models (or linear regression models in the case of secondary outcomes) with participant-level data from relevant studies within UCLEB consortium (BRHS, BWHHS, MRC-NHSD) and summary-level data 
from the published meta-analyses of Kunutsor et al (2013) and Fraser et al (2009). We also estimated the association of liver function markers with T2D risk (or secondary outcomes) using a Mendelian 
randomization approach. In Mendelian randomization analysis, we used different data sources to estimate the SNP-liver function marker association (UCLEB consortium — BRHS, BWHHS and MRC-
NHSD —, Fenland study, and GWAS of liver function markers — Chambers et al (2011)) —, and SNP-T2D risk association (UCLEB — BRHS, BWHS, CaPS, EAS, ELSA, MRC-NHSD, and WHII —, 
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and GWAS consortium) or SNP-secondary outcomes. As shown in figure 1B, the summary-level data for the association of SNP-T2D risk and SNP-fasting insulin for the reverse MR was extracted from 
GWAS consortia, and the association of SNP-liver function marker was extracted from Chambers et al (2011). ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; 
BMI: body mass index;  BRHS: British Regional Heart Study; BWHHS: British Women’s Heart and Health Study; CaPS: Caerphilly Prospective Study; DIAGRAM consortium:  Diabetes Genetics 
Replication And Meta-analysis consortium; EAS: Edinburgh Artery Study; ELSA: English Longitudinal Study of Ageing; GGT: gamma-glutamyl transferase; GWAS: genome-wide association study; 
HDL-C: high density lipoprotein-cholesterol; LDL-C: low density lipoprotein-cholesterol; MRC-NSHD: National Survey of Health and Development; SNPs: single nucleotide polymorphisms; T2D: type 2 
diabetes; UCLEB consortium: UCL-LSHTM-Edinburgh-Bristol consortium; WHII: Whitehall II study.
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Figure 2. Multivariable and Mendelian randomization analysis of the effect of liver function on T2D (A) and Mendelian randomization analysis of 
the effect of T2D on liver function markers (B). 
Results from Figure 1A correspond to odds ratio of T2D per unit increase in standardized liver function markers (and 95% confidence interval). Results from 
Figure 1B correspond to change in standardized liver function markers per unit increase in log odds of T2D (and 95% confidence interval). I-squared indicates 
between-study heterogeneity and is only presented when estimates for more than one study were available. ALT: alanine aminotransferase; AST: aspartate 
aminotransferase; ALP: alkaline phosphatase; GGT: gamma-glutamyl transferase; SNPs: single nucleotide polymorphisms; T2D: type 2 diabetes.
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Supplementary table 1. Number of participants with data on exposures, outcomes and covariates/potential confounders in UCLEB and Fenland studies used 
in the multivariable and Mendelian randomization analyses
*Variable types as used in the multivariable/Mendelian randomization study. 
$Only the multivariable analyses were adjusted for these confounders. 
**Number of individuals with non-missing data for each trait in the analysis sample. For each UCLEB study, we included individuals who had complete data for all available 
genetic variants, age, sex, the liver function markers measured in the study, and were not on lipid lowering medication. For those studies that were only used to estimate the 
gene-outcome association (i.e.: studies where none of the liver function markers were available), we included individuals who had complete data for all available genetic variants, 
age and sex only.
ALT: alanine aminotransferase; ALP: alkaline phosphatase; AST: aspartate aminotransferase; GGT: gamma-glutamyl transferase; BMI: body mass index; UCLEB consortium: UCL-LSHTM-
Edinburgh-Bristol consortium – BRHS: British Regional Heart Study; BWHHS: British Women’s Heart and Health Study; CaPS: Caerphilly Prospective Study; EAS: Edinburgh Artery Study; ELSA: 
English Longitudinal Study of Ageing; NSHD: MRC National Survey of Health and Development, WHII: Whitehall II study.
Trait Variable type* Available studies Total N**
ALT (U/L) Exposure BRHS, BWHHS, NSHD & Fenland 15371
ALP (U/L) Exposure CAPS, NSHD & Fenland 12761
AST (U/L) Exposure BRHS, BWHHS, CAPS & NSHD 6624
GGT (U/L) Exposure BRHS, BWHHS, CAPS, EAS, NSHD & Fenland 17336
Fasting glucose (mmol/l) Continuous outcome BRHS, BWHHS, CAPS, EAS, ELSA, NSHD & WHII 9689
Fasting insulin (μIU/ml) Continuous outcome BRHS, BWHHS, CAPS, NSHD & WHII 7024
LDL cholesterol (mmol/L) Continuous outcome BRHS, BWHHS, CAPS, EAS, ELSA, WHII, NSHD & Fenland 21296
HDL cholesterol (mmol/L) Continuous outcome BRHS, BWHHS, CAPS, EAS, ELSA, WHII, NSHD & Fenland 21464
Total cholesterol (mmol/L) Continuous outcome BRHS, BWHHS, CAPS, EAS, ELSA, WHII, NSHD & Fenland 21639
Triglycerides (mmol/l) Continuous outcome BRHS, BWHHS CAPS, EAS, ELSA, WHII, NSHD & Fenland 20856
Type 2 diabetes cases 1202
Type 2 diabetes controls
Disease outcome BRHS, BWHHS, CAPS, EAS, ELSA, WHII, NSHD
10588
Age (years) Covariate/Potential Confounder BRHS, BWHHS CAPS, EAS, ELSA, WHII, NSHD & Fenland 21772
BMI (kg/m2)$ Potential confounder BRHS, BWHHS CAPS, EAS, ELSA, WHII, NSHD & Fenland 21513
Waist circumference (cm)$ Potential confounder BRHS, BWHHS, ELSA, WHII, NSHD & Fenland 19595
Sex Covariate/Potential confounder BRHS, BWHHS CAPS, EAS, ELSA, WHII, NSHD & Fenland 21772
Smoking$ Potential confounder BRHS, BWHHS, CAPS, EAS, ELSA, WHII, NSHD & Fenland 21631
Alcohol consumption$ Potential confounder BRHS, BWHHS, CAPS, EAS, ELSA, WHII, NSHD & Fenland 21501
Social class$ Potential confounder BRHS, BWHHS, CAPS, EAS, ELSA, NSHD & Fenland 8563
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Supplementary table 2a. Distribution of participant characteristics (continuously measured variables) within each UCLEB study and the Fenland study 
Variable BRHS BWHHS CAPS EAS ELSA WHII NSHD Fenland
N1 2090 1733 1221 762 1688 2716 1580 9982
Age (years) 69.01 (5.66) 71.55 (5.31) 56.74 (4.47) 64.51 (5.64) 73.93 (9.60) 60.39 (5.91) 53 (N/A) 48.14 (7.44)
BMI (kg/m2) 2
26.48 (24.47, 
28.83)
[2077]
27 (24, 30)
[1714]
26.44 (24.40, 
28.67)
[1202]
25.21 (23.15, 
27.40)
[762]
26.91 (24.36, 
29.96)
[1571]
26.00 (23.80, 
28.60)
[2708]
26.32 (24.15, 
29.34)
[1574]
26.16 (29.31-
23.56)
[9905]
Waist circumference 
(cm)
96.71 (10.22)
[2071]
86.35 (12.28)
[1707] Not available Not available
95.91 (12.78)
[1627]
91.29 (12.18)
[2713]
90.48 (12.70)
[1578]
90.86 (13.43)
[9899]
Physical activity (m/s2) 3 Not available Not available Not available Not available Not available Not available Not available 0.11 (0.09, 0.15)
ALT (U/L) 2 15 (12, 20) 12 (9, 15) Not available Not available Not available Not available 26 (21, 34) 25 (19, 34) [9968]
ALP (U/L) 2 Not available Not available 89 (75, 105) Not available Not available Not available 79 (67, 94) 83 (69, 98)[9960]
AST (U/L) 2 23 (19, 27) 22 (19, 25) 19 (16, 23) Not available Not available Not available 24 (21, 29) Not available
GGT (U/L)2 26 (19, 38) 20 (14, 31) 30 (22, 44) 22.50 (16.13, 33.29) Not available Not available 29.6 (21.6, 42.3)
26 (20, 38)
[9950]
Fasting glucose 
(mmol/L) 2,4
5.30 (0.65)
[1820]
5.70 (0.50)
[1498]
5.10 (0.49)
[1055]
5.52 (0.55)
[685]
4.90 (0.49)
[702]
5.26 (0.49)
[2509]
5.48 (0.56)
[1420] Not available
Fasting insulin (μIU/ml) 
2,4
7.70 (5.20, 
11.30)
[1813]
6.10 (4.40, 9.20)
[1498]
4.82 (3.17, 7.10)
[535] Not available Not available
6.7 (4.6, 10.1)
[2438]
42 (28, 60)
[740] Not available
LDL cholesterol 
(mmol/L)
3.96 (0.98)
[2060]
4.25 (1.07)
[1687]
3.72 (0.88)
[1178]
5.35 (1.24)
[759]
3.49 (1.05)
[1645]
3.62 (0.87)
[2683]
3.53 (0.94)
[1374]
3.43 (0.90)
[9910]
HDL cholesterol 
(mmol/L)
1.15 (0.25)
[2004]
1.62 (0.45)
[1731]
1.02 (0.25)
[1214]
1.45 (0.37)
[759]
1.50 (0.39)
[1677]
1.57 (0.45)
[2715]
1.70 (0.51)
[1382] 1.53 (0.41)
Total cholesterol 
(mmol/L)
6.29 (0.99)
[2082]
6.73 (1.20)
[1733]
5.60 (0.99)
[1214]
7.10 (1.33)
[762]
5.79 (1.27)
[1678]
5.80 (0.95)
[2715]
6.10 (1.03)
[1473] 5.45 (1.02)
Triglycerides (mmol/L) 2 1.71 (1.2, 2.48)[1302]
1.62 (1.21, 2.30)
[1733]
1.64 (1.18, 2.34)
[1214]
1.35 (1.01, 1.78)
[762]
1.50 (1.1, 2.2)
[1678]
1.10 (0.80, 1.60)
[2715]
1.7 (1.2, 2.5)
[1470] 1.0 (0.7, 1.4)
1 Number of individuals in the analysis sample of the Mendelian randomization study. The analysis sample for each UCLEB study included individuals who had complete data 
for all available SNPs, age, sex, the liver function markers measured in the study, and were not on lipid lowering medication. Note that the analysis sample in UCLEB was not 
defined based on the availability of complete data for the potential confounders and the outcome variables. Therefore, the number of individuals included in analyses involving 
the confounders and the outcome variables depends on the number of individuals with non-missing data for each outcome /confounder variable in a given study and is given 
in brackets if it differed from the N in the analysis sample. Analysis sample in the Fenland study included individuals who were not on lipid lowering medication and had 
complete data on age, sex and at least 80% of the SNPs available. 
2 Distributions for these variables are median (interquartile range; IQR) because the distributions were right skewed; all other results are means (standard deviation; SD).
3 Physical activity was assessed as average acceleration trunk longitudinal axis (m/s2).
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4 For fasting glucose and fasting insulin we removed individuals with type 2 diabetes and/or fasting glucose values ≥ 7.0 mol/L and/or individuals who were taking glucose 
lowering drugs. 
ALT: alanine aminotransferase; ALP: alkaline phosphatase; AST: aspartate aminotransferase; GGT: gamma-glutamyl transferase BMI: body mass index; UCLEB consortium: UCL-LSHTM-
Edinburgh-Bristol consortium – BRHS: British Regional Heart Study; BWHHS: British Women’s Heart and Health Study; CaPS: Caerphilly Prospective Study; EAS: Edinburgh Artery Study; 
ELSA: English Longitudinal Study of Ageing; NSHD: MRC National Survey of Health and Development, WHII: Whitehall II study; HDL-C: high density lipoprotein-cholesterol; LDL-C: low density 
lipoprotein-cholesterol
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Supplementary table 2b. Distribution of participant characteristics (categorical variables) within each UCLEB study and the Fenland study
Variable BRHS BWHHS CaPS EAS ELSA WHII NSHD Fenland
N* 2090 1733 1221 762 1688 2716 1580 9982
Men 2090 0 1221 369 882 2073 747 4606
Women 0 1733 0 393 806 643 833 5376Sex
Missinga 0 0 0 0 0 0 0 0
Never smokers 585 933 240 292 573 1345 472 5329
Ever smokers 1503 800 978 456 1115 1368 1033 4609Smoking
Missinga 2 0 3 14 0 3 75 44
Never 78 306 70 83 173 67 309 1556
Ever 1953 1258 1147 679 1515 2623 1271 8413Alcohol consumption Missing 59 169 4 0 0 26 0 13
Unskilled 62 135 59 25 344 52
Semi-skilled 168 171 224 56 325 147
Manual skilled 850 432 707 187 350 232
Non-manual skilled 192 214 173 139 365 359
Managerial and 
lower professional 567 282 57 263 290 619
Professional 191 124 0 88 0
Not available
114
Not availableSocial class
Missing 60 375 1 4 14 N/A 57 N/A
Yes 251 230 149 76 210 159 127
No 1839 1503 1072 686 1478 2557 1453 Not availableType 2 Diabetes
Missing 0 0 0 0 0 0 0 N/A
* Number of individuals in the analysis sample of the Mendelian randomization study. The analysis sample for each study included individuals who had complete data for all 
available SNPs, age, sex, the liver function markers measured in the study, and were not on lipid lowering medication. N/A: not applicable. UCLEB consortium: UCL-LSHTM-
Edinburgh-Bristol consortium – BRHS: British Regional Heart Study; BWHHS: British Women’s Heart and Health Study; CaPS: Caerphilly Prospective Study; EAS: Edinburgh 
Artery Study; ELSA: English Longitudinal Study of Ageing; NSHD: MRC National Survey of Health and Development, WHII: Whitehall II study.
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Supplementary table 3. List of index SNPs associated with ALT, AST, ALP and GGT at genome-wide levels of significance (P<5 x10-8) selected from 
published GWAS studies1 
Index SNP 
from GWAS
Associated 
liver 
function 
marker
Chr Mapped gene/s2 Publication Index SNP selected from
Index SNP in all 
relevant UCLEB 
studies
Genotyped/ 
imputed in 
UCLEB 
studies
Index 
SNP in 
Fenlan
d study
Genotyped/ 
imputed in 
Fenland
Proxy SNP used if 
applicable
R2 of proxy 
with index 
SNP
rs6834314 ALT 4 HSD17B13, MAPK10 Chambers et al_2011 Yes imputed Yes imputed N/A N/A
rs2954021 ALP/ALT 8 TRIB1 Chambers et al_2011 Yes imputed Yes imputed N/A N/A
rs11597390 ALT 10 CPN1 Yuan et al_2008 Yes genotyped Yes genotyped N/A N/A
rs2143571 ALT 22 SAMM50 Yuan et al_2008 Yes imputed Yes genotyped N/A N/A
rs17109512 AST 10 GOT1 Shen et al_2011 Yes except in CAPS and EAS 3 imputed Yes genotyped rs7073497 1.00
rs738407 AST 22 PNPLA3 Novel Yes imputed Yes imputed N/A N/A
rs738408 AST 22 PNPLA3 Novel Yes imputed Yes imputed N/A N/A
rs1780324 ALP 1 NBPF3-ALPL Yuan et al_2008 Yes genotyped Yes genotyped N/A N/A
rs16856332 ALP 2 ABCB11 Chambers et al_2011 No N/A Yes genotyped rs11892966 1.00
rs9467160 ALP 6 GPLD1 Yuan et al_2008 Yes imputed Yes genotyped N/A N/A
rs6984305 ALP 8 PPP1R3B Chambers et al_2011 Yes genotyped Yes genotyped N/A N/A
rs514708 ALP 9 ABO Yuan et al_2008 Yes genotyped No N/A rs8176714 1.00
rs10819937 ALP 9 ALDOB, C9orf125 Chambers et al_2011 No N/A Yes genotyped No suitable proxy SNP (R2 ≥ 0.8) in UCLEB N/A
rs579459 ALP 9 ABO Chambers et al_2011 Yes genotyped Yes genotyped N/A N/A
rs7923609 ALP 10 JMJD1C, NRBF2 Chambers et al_2011 Yes genotyped Yes genotyped N/A N/A
rs174601 ALP 11 C11orf10, FADS1, FADS2 Chambers et al_2011 Yes genotyped Yes genotyped N/A N/A
rs2236653 ALP 11 ST3GAL4 Chambers et al_2011 Yes imputed Yes imputed N/A N/A
rs7186908 ALP 16 HPR, PMFBP1 Chambers et al_2011 Yes imputed Yes imputed N/A N/A
rs314253 ALP 17 ASGR1, DLG4 Chambers et al_2011 Yes genotyped Yes genotyped N/A N/A
rs281377 ALP 19 FUT2 Chambers et al_2011 Yes imputed Yes genotyped N/A N/A
rs7267979 ALP 20 ABHD12, GINS1, PYGB Chambers et al_2011 Yes genotyped Yes genotyped N/A N/A
rs1497406 GGT 1 RSG1, EPHA2 Chambers et al_2011 Yes imputed Yes genotyped N/A N/A
rs12145922 GGT 1 CCBL2, PKN2 Chambers et al_2011 Yes imputed Yes genotyped N/A N/A
rs1335645 GGT 1 CEPT1, DENNDD Chambers et al_2011 No N/A Yes genotyped No suitable proxy SNP (R2 ≥ 0.8) in UCLEB N/A
rs10908458 GGT 1 DPM3, EFNA1,PKLR Chambers et al_2011 Yes imputed Yes imputed N/A N/A
rs1260326 GGT 2 C2orf16, GCKR Chambers et al_2011 Yes genotyped Yes genotyped N/A N/A
rs13030978 GGT 2 MYO1B, STAT4 Chambers et al_2011 Yes imputed Yes genotyped N/A N/A
rs2140773 GGT 2 EFHD1, LOC100129166 Chambers et al_2011 Yes except in the EAS 4 genotyped Yes genotyped
No suitable proxy SNP 
(R2 ≥ 0.8) in EAS N/A
rs10513686 GGT 3 SLC2A2 Chambers et al_2011 Yes genotyped Yes genotyped N/A N/A
rs4547811 GGT 4 ZNF827 Chambers et al_2011 Yes imputed Yes genotyped N/A N/A
rs6888304 GGT 5 CDH6 Chambers et al_2011 No N/A Yes genotyped No suitable proxy SNP (R2 ≥ 0.8) in UCLEB N/A
rs4074793 GGT 5 ITGA1 Chambers et al_2011 Yes imputed Yes genotyped N/A N/A
rs9296736 GGT 6 MLIP Chambers et al_2011 Yes genotyped Yes imputed N/A N/A
rs17145750 GGT 7 MLXIPL Chambers et al_2011 Yes genotyped Yes genotyped N/A N/A
rs754466 GGT 10 DLG5 Chambers et al_2011 No N/A Yes imputed No suitable proxy SNP (R2 ≥ 0.8) in UCLEB N/A
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rs7310409 GGT 12 HNF1A, C12orf7 Chambers et al_2011 Yes genotyped Yes genotyped N/A N/A
rs944002 GGT 14 C14orf73 Chambers et al_2011 Yes imputed Yes genotyped N/A N/A
rs339969 GGT 15 RORA Chambers et al_2011 Yes imputed Yes genotyped N/A N/A
rs8038465 GGT 15 CD276 Chambers et al_2011 No  except in the BRHS study 5 imputed Yes genotyped rs62004612 0.87
rs4581712 GGT 16 DYNLRB2 Chambers et al_2011
Yes except in 
BWHHS, EAS and 
CAPS 6
imputed Yes genotyped
No suitable proxy SNP 
present in BWHHS, EAS 
and CAPS stuies
N/A
rs9913711 GGT 17 FLJ37644, SOX9 Chambers et al_2011 No N/A Yes genotyped No suitable proxy SNP (R2 ≥ 0.8) in UCLEB N/A
rs12968116 GGT 18 ATP8B1 Chambers et al_2011 No N/A Yes genotyped No suitable proxy SNP (R2 ≥ 0.8) in UCLEB N/A
rs4503880 GGT 18 NEDD4L Chambers et al_2011 No N/A Yes imputed No suitable proxy SNP (R2 ≥ 0.8) in UCLEB N/A
rs516246 GGT 19 FUT2 Chambers et al_2011 Yes genotyped Yes genotyped N/A N/A
rs4820599 GGT 22 GGT1 Yuan et al_2008 Yes genotyped Yes genotyped N/A N/A
rs1076540 GGT 22 MICAL3 Chambers et al_2011 Yes imputed Yes genotyped N/A N/A
rs2739330 GGT 22 DDT, DDTL, GSTT1, GSTT2B, MIF Chambers et al_2011 Yes imputed Yes imputed N/A N/A
1 SNPs mapped to the same gene, as reported in the original GWAS publications, were considered as part of the same locus. For loci where the index SNP reported for the same locus was 
different in independent publications, we selected the SNP that was genotyped in the UCLEB studies. If the different index SNPs reported in independent publications for the same locus were all 
imputed or genotyped in UCLEB, we selected the one that showed the strongest association in the largest GWAS study. We used a proxy SNP (R2 ≥ 0.8) if the index SNP was not present across 
all or some of relevant the UCLEB studies. If there was more than one eligible proxy, we selected the proxy that was genotyped in the UCLEB studies, and if all eligible proxies were genotyped or 
imputed we selected a proxy SNP in random. There were seven index SNPs in total (one SNP associated with ALP and six SNPs associated with GGT) that were not genotyped/imputed in any 
of the UCLEB studies, and did not have a suitable proxy available. These SNPs were therefore not included as genetic instruments in the UCLEB studies. However, all SNPs (or a suitable proxy) 
associated with a given liver function marker were available in the GWAS and Fenland studies, and were used as genetic instruments in those studies. One further GWAS has been published 
since we completed our search (July 2017), which found a novel rare variant associated with ALT (rs28929474; MAF=2%). Given that this variant is rare and is not available in T2D GWAS, which 
is the largest dataset contributing to the MR estimates, we have not included it in our analyses as it would add little information.
2 Mapped gene for each SNP is given as reported in the original publication. 
3 Index SNP was absent in CAPS and EAS studies therefore we used the SNP rs7073497 in UCLEB studies, which is perfectly correlated with the index SNP and was available across all 
UCLEB studies. 
4 This SNP was not present in EAS study and there was no suitable proxy SNP present across all studies. Therefore, we did not use the EAS study to estimate the SNP-exposure and SNP-
outcome for this locus.
5 This SNP was used instead of the index SNP as it was present across all the relevant UCLEB studies and is correlated at R2=0.87 with the index SNP. 
6 This SNP was absent in BWHHS, EAS and CAPS and there was no suitable proxy that was available across all studies. Therefore, we did not use the BWHHS, EAS and the CAPS study to 
estimate the SNP-exposure and SNP-outcome for this locus.
ALT: alanine aminotransferase; ALP: alkaline phosphatase; AST: aspartate aminotransferase; GGT: gamma-glutamyl transferase; SNPs: single nucleotide polymorphisms; UCLEB 
consortium: UCL-LSHTM-Edinburgh-Bristol consortium; GWAS: Genome-wide association study
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Supplementary table 4. Association of novel variants with AST plasma concentration in the replication sample (NFBC1966 and NSHD studies)
SNP Study N Effect size (SD units) SE P-value MAF
rs738407 NFBC1966 3614 0.043 0.022 0.049 0.48
rs738407 NSHD 1580 0.088 0.057 0.120 0.34
Overall 5194 0.049 0.020 0.017
rs738408 NFBC1966 3614 0.071 0.026 0.006 0.23
rs738408 NSHD 1580 0.087 0.050 0.080 0.16
Overall 5194 0.075 0.023 0.001  
The genome-wide association analyses were carried out in each individual study (BRHS, BWHHS, CaPS, EAS, and ET2DS) using the SnpStats software in R. The individual study estimates were 
combined using the inverse variance- fixed effect meta-analysis using the METAL software. Monomorphic SNPs, SNPs that were not sufficiently well imputed (Rsq < 0.3), and SNPs with MAF 
<0.001 were filtered out prior to meta-analyses. Genome-wide significance was inferred at p< 5 x 10-8. Two novel variants (rs738407 and rs738408) near PNPLA3 gene were associated with AST 
at genome-wide levels of significance (P<5 x 10-8) in the discovery stage and were replicated in the MRC NHSD study (n = 1,580) (1) and 1966 Northern Finland Cohort (NFBC1966) (n = 3,614) 
(2).  AST: aspartate aminotransferase; BRHS: British Regional Heart Study; BWHHS: British Women’s Heart and Health Study; CaPS: Caerphilly Prospective Study; EAS: Edinburgh Artery Study; 
ET2DS: Edinburgh Type 2 Diabetes Study; MAF: minor allele frequency; NSHD: MRC National Survey of Health and Development; NFBC1966: Northern Finland Birth Cohort 1966; SD: standard 
deviation; SNP: single nucleotide polymorphism; UCLEB consortium: UCL-LSHTM-Edinburgh-Bristol consortium.
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Supplementary table 5. The associations of individual SNPs (used as genetic instruments for type 2 
diabetes risk in Mendelian randomization analyses) with type 2 diabetes 
SNP
Effect 
allele
Other 
allele Beta SE P-value
rs2296173 G A 0.065 0.009 7.7E-14
rs12088739 G A -0.088 0.013 9.8E-12
rs1127655 C T 0.044 0.008 2.5E-08
rs2493394 G A 0.073 0.011 1.2E-10
rs340874 T C -0.063 0.007 8.4E-18
rs2820426 A G -0.052 0.007 1.3E-12
rs348330 G A 0.049 0.008 1.9E-09
rs2867125 T C -0.060 0.010 4.3E-10
rs780094 T C -0.069 0.007 5.2E-21
rs17334919 T C -0.140 0.013 6.7E-28
rs243019 C T 0.057 0.007 2.3E-15
rs1009358 C T -0.055 0.008 9.8E-12
rs10169613 T C -0.043 0.008 3.6E-08
rs12617659 T C -0.069 0.010 2.8E-11
rs7572970 A G -0.059 0.009 1.4E-11
rs13389219 T C -0.072 0.007 2.1E-22
rs2972144 A G -0.091 0.008 2.6E-34
rs7561798 G A 0.040 0.007 2.8E-08
rs1899951 T C -0.112 0.011 1.6E-24
rs1496653 G A -0.077 0.009 2.6E-18
rs11926707 T C -0.046 0.008 1.7E-08
rs2292662 T C -0.063 0.011 1.2E-08
rs6795735 T C -0.056 0.007 1.6E-14
rs11708067 G A -0.097 0.009 5.9E-29
rs9844972 C G 0.096 0.015 1.0E-10
rs4472028 T C 0.045 0.007 2.1E-10
rs11925227 A G -0.053 0.010 2.3E-08
rs7651090 G A 0.120 0.008 3.9E-57
rs3887925 C T -0.047 0.008 2.5E-09
rs6808574 T C -0.055 0.008 4.4E-13
rs1801214 C T -0.090 0.007 5.5E-34
rs17086692 T G -0.047 0.008 2.5E-08
rs993380 A G 0.051 0.008 4.6E-10
rs7674212 T G -0.047 0.008 6.2E-10
rs11098676 T C -0.054 0.010 2.0E-08
rs7685296 T C -0.051 0.008 2.3E-10
rs735949 C T -0.071 0.011 1.9E-11
rs1061813 G A 0.043 0.007 3.4E-09
rs4865796 G A -0.053 0.008 1.3E-11
rs459193 A G -0.071 0.008 8.8E-18
rs3900856 A G 0.114 0.019 7.4E-10
rs2307111 C T -0.041 0.007 3.0E-08
rs7729395 T C 0.137 0.016 1.1E-17
rs10077431 A C -0.049 0.009 4.8E-08
rs1050226 G A -0.049 0.007 3.3E-11
rs7756992 G A 0.130 0.008 6.0E-62
rs2857605 C T -0.067 0.009 5.9E-14
rs2071479 T C 0.147 0.023 6.6E-11
rs9369425 G A 0.055 0.009 1.1E-10
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rs72892910 T G 0.065 0.010 6.4E-11
rs853974 T C 0.060 0.009 7.9E-12
rs2246012 C T 0.053 0.009 2.4E-08
rs622217 C T -0.049 0.008 3.1E-10
rs17168486 T C 0.074 0.009 2.2E-15
rs2191348 G T -0.065 0.007 3.4E-19
rs849135 G A 0.100 0.007 1.0E-43
rs2908282 A G 0.055 0.009 4.3E-09
rs2299383 T C 0.041 0.007 1.5E-08
rs13239186 T C 0.054 0.009 2.7E-10
rs13234269 A T -0.058 0.008 7.0E-14
rs7786095 G A -0.074 0.013 9.6E-09
rs7841082 T C -0.042 0.008 4.9E-08
rs11774915 T C 0.050 0.009 8.7E-09
rs10100265 A C 0.049 0.008 6.3E-10
rs17411031 G C -0.045 0.008 3.0E-08
rs10087241 G A 0.048 0.008 2.8E-09
rs12681990 C T 0.063 0.010 3.6E-11
rs516946 T C -0.082 0.009 3.2E-22
rs7845219 C T -0.042 0.007 4.5E-09
rs3802177 A G -0.122 0.008 2.3E-52
rs2294120 G A -0.044 0.008 1.6E-08
rs10974438 C A 0.059 0.008 3.0E-15
rs1063192 G A -0.063 0.007 3.3E-18
rs10811661 C T -0.157 0.010 4.1E-58
rs1758632 C G -0.049 0.008 1.4E-09
rs17791483 G A -0.102 0.015 3.4E-12
rs2796441 A G -0.072 0.007 2.0E-22
rs10114341 C T -0.041 0.007 1.2E-08
rs687621 G A 0.043 0.008 1.4E-08
rs11257655 T C 0.074 0.009 2.0E-17
rs2616132 A G 0.046 0.008 6.6E-09
rs2633310 T G -0.044 0.008 2.4E-08
rs753270 T C -0.053 0.008 2.7E-11
rs7923866 T C -0.097 0.007 9.3E-40
rs11591741 C G -0.048 0.008 1.2E-09
rs7903146 T C 0.306 0.008 1.0E-200
rs4918796 C T 0.062 0.009 4.0E-13
rs2421016 T C -0.046 0.007 1.5E-10
rs2237892 T C -0.096 0.016 8.7E-10
rs5215 C T 0.068 0.007 2.1E-20
rs7929543 C A 0.083 0.014 2.2E-09
rs1552224 C A -0.103 0.010 8.6E-25
rs10830963 G C 0.091 0.008 5.8E-30
rs7931302 C A 0.046 0.008 7.7E-09
rs67232546 T C 0.060 0.010 4.7E-10
rs11048456 C T 0.049 0.008 3.0E-09
rs10842994 T C -0.076 0.009 1.0E-16
rs2261181 T C 0.099 0.012 9.2E-17
rs1480474 G A 0.041 0.007 1.7E-08
rs7138300 C T 0.044 0.007 5.6E-10
rs11107116 T G 0.047 0.009 3.8E-08
rs61953351 T G -0.070 0.009 2.0E-14
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rs940904 G A -0.050 0.008 2.1E-09
rs825476 C T -0.052 0.007 6.8E-13
rs576674 G A 0.065 0.010 1.8E-11
rs963740 T A -0.048 0.009 2.2E-08
rs1359790 A G -0.080 0.008 2.8E-23
rs7144011 T G 0.048 0.009 1.6E-08
rs4502156 C T -0.041 0.007 1.7E-08
rs982077 A G 0.045 0.007 2.6E-10
rs7177055 G A -0.065 0.008 2.7E-16
rs4932143 G C 0.057 0.009 5.5E-11
rs12910825 G A 0.052 0.007 2.2E-12
rs9940149 A G -0.058 0.010 9.3E-10
rs7185735 G A 0.106 0.007 1.6E-47
rs244415 A G -0.047 0.008 3.9E-09
rs77258096 A C -0.117 0.013 1.8E-18
rs2925979 T C 0.053 0.008 9.1E-12
rs8068804 A G 0.059 0.008 4.4E-14
rs12945601 T C 0.048 0.008 1.7E-09
rs17405722 A G 0.087 0.015 2.3E-09
rs9911983 C T -0.040 0.007 4.8E-08
rs9894220 G A -0.059 0.008 1.5E-13
rs302864 A G 0.071 0.013 2.5E-08
rs17631783 T C -0.049 0.009 3.9E-08
rs7240767 C T 0.045 0.008 2.2E-08
rs12970134 A G 0.056 0.008 5.3E-12
rs10401969 C T 0.092 0.013 4.1E-12
rs8108269 G T 0.064 0.008 3.1E-16
rs6515236 C A -0.050 0.009 3.3E-08
rs6059662 A G -0.045 0.008 1.5E-08
rs4810426 T C 0.073 0.013 2.1E-08
rs6066138 A G -0.049 0.008 1.9E-09
rs16988333 G A -0.075 0.013 9.2E-09
rs4823182 G A 0.048 0.008 3.4E-10
rs6878122 G A 0.056 0.008 1.2E-12
rs11651755 C T 0.074 0.008 9.0E-22
rs12299509 G A 0.047 0.007 2.1E-10
rs1063355 T G -0.071 0.008 3.7E-19
SNP: single nucleotide polymorphism; SE: standard deviation. Beta and SE expressed as change in log odds ratio of T2D per 
effect allele.
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Supplementary table 6. The associations of individual SNPs (used as genetic instruments for fasting 
insulin in Mendelian randomization analyses) with fasting insulin
SNP Effect allele
Other 
allele
Effect allele 
frequency Beta SE P-value
rs10195252 C T 0.44 -0.02025 0.003291 4.87E-10
rs1121980 G A 0.48 -0.02532 0.003165 8.36E-16
rs1167800 A G 0.45 0.020253 0.003291 2.61E-09
rs1260326 C T 0.42 0.024051 0.003291 3.84E-14
rs1530559 A G 0.40 0.017722 0.003291 3.37E-08
rs2745353 T C 0.45 0.017722 0.003165 5.48E-09
rs2820436 C A 0.32 0.018987 0.003291 4.36E-09
rs2972143 G A 0.37 0.017722 0.003291 3.15E-08
rs4865796 A G 0.29 0.018987 0.003291 2.09E-08
rs731839 A G 0.34 -0.01772 0.003291 1.72E-08
rs7903146 C T 0.28 0.022785 0.003544 6.13E-11
rs860598 A G 0.14 0.022785 0.004051 1.64E-08
rs983309 G T 0.10 -0.03671 0.00481 3.81E-14
rs9884482 T C 0.35 -0.02025 0.003038 1.40E-11
SNP: single nucleotide polymorphism; SE: standard deviation. Beta and SE expressed as change in fasting insulin (in SD log 
pmol/L) per effect allele.
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Supplementary table 7a. Association of liver function markers-related SNPs with continuous potential confounders of the exposure-outcome associations 
meta-analysed across the relevant UCLEB studies and GIANT consortium data
Potential confounders (Effect size per copy of the liver enzyme raising allele (95% CI))
SNP/ 
instrument Age (years) BMI (SD)*
Waist 
circumference (SD)*
Waist-hip ratio 
(SD)* ALT (SD) AST (SD) GGT (SD) ALP (SD)
rs11597390 -0.13 (-0.30, 0.03) 0.00 (-0.01, 0.01) 0.01 (0.00, 0.02) 0.00 (-0.00, 0.01) N/A 0.06 (0.03, 0.10) 0.03 (-0.00, 0.06) -0.08 (-0.13, -0.02)
rs2143571 -0.04 (-0.26, 0.17) 0.00 (-0.01, 0.01) 0.00 (-0.01, 0.01) 0.00 (-0.01, 0.01) N/A 0.12 (0.07, 0.17) 0.05 (-0.00, 0.09) 0.03 (-0.04, 0.11)
rs2954021 -0.11(0.27, 0.05) -0.01(-0.02, -0.00) -0.01 (-0.01, 0.00) 0.00 (-0.01, 0.01) N/A -0.00 (-0.03, 0.03) 0.03 (-0.01, 0.06) 0.08 (0.03, 0.13)
rs6834314 0.04(-0.13, 0.22) -0.01 (-0.02, -0.01) -0.01 (-0.02, 0.00) -0.00 (-0.01, 0.01) N/A 0.04 (0.00, 0.08) 0.03 (-0.00, 0.07) -0.03 (-0.09, 0.03)
ALT 
instrument -0.07 (-0.16, 0.02) -0.00 (-0.01, 0.00) -0.00 (-0.00, 0.00) 0.00 (-0.00, 0.01) N/A 0.05 (0.03, 0.07) 0.03 (0.01, 0.05) -0.00 (-0.03, 0.03)
rs17109512 -0.27 (-0.99, 0.39) 0.00 (-0.02, 0.02) -0.01 (-0.03, 0.01) -0.00 (-0.03, 0.02) -0.16 (-0.31, 0.00) N/A -0.12 (-0.26, 0.02) -0.13 (-0.38, 0.13)
rs738407 -0.05 (-0.30, 0.21) -0.00 (-0.01, 0.00) -0.00 (-0.01, 0.01) -0.00 (-0.01, 0.01) 0.13 (0.07, 0.19) N/A 0.02 (-0.03, 0.07) 0.03 (-0.05, 0.12)
rs738408 -0.04 (-0.27, 0.19) -0.01 (-0.01, 0.00) -0.00 (-0.01, 0.01) 0.00 (-0.01, 0.01) 0.13 (0.07, 0.18) N/A 0.01 (-0.03, 0.06) 0.02 (-0.05, 0.10)
AST 
instrument -0.06 (-0.22, 0.11) -0.00 (-0.01, 0.00) -0.00 (-0.01, 0.00) -0.00 (-0.01, 0.01) 0.11 (0.07, 0.15) N/A 0.01 (-0.03, 0.04) 0.02 (-0.04, 0.07)
rs16856332 0.13 (-0.41, 0.68) -0.01 (-0.03, 0.00) -0.02 (-0.04, 0.00) -0.01 (-0.03, 0.02) 0.04 (-0.09, 0.17) -0.06 (-0.18, 0.06) -0.11 (-0.23, -0.00) N/A
rs174601 -0.04 (-0.20, 0.12) 0.00 (-0.00, 0.01) 0.00 (-0.00, 0.01) 0.00 (-0.00, 0.01) -0.02 (-0.06, 0.01) 0.00 (-0.03, 0.04) 0.00 (-0.03, 0.04) N/A
rs1780324 -0.03 (-0.18, 0.13) -0.00 (-0.01, 0.00) -0.00 (-0.01, 0.00) -0.00 (-0.01, 0.00) -0.01 (-0.05, 0.02) -0.01 (-0.04, 0.03) 0.01 (-0.03, 0.04) N/A
rs2236653 0.16 (-0.02, 0.33) -0.00 (-0.01, 0.01) -0.00 (-0.01, 0.01) -0.00 (-0.01, 0.01) -0.00 (-0.04, 0.04) -0.00 (-0.04, 0.03) 0.02 (-0.01, 0.06) N/A
rs281377 0.16 (0.00, 0.33) 0.01 (0.00, 0.02) 0.01 (0.00, 0.02) -0.01 (-0.01, 0.00) 0.00 (-0.04, 0.04) 0.00 (-0.03, 0.04) -0.05 (-0.08, -0.01) N/A
rs2954021 -0.11 (-0.27, 0.05) -0.01 (-0.02, -0.00) -0.01 (-0.01, 0.00) 0.00 (-0.01, 0.01) 0.03 (-0.00, 0.07) -0.00 (-0.03, 0.03) 0.03 (-0.01, 0.06) N/A
rs314253 0.15 (-0.02, 0.31) -0.000 (-0.01, 0.01) -0.00 (-0.01, 0.01) -0.01 (-0.01, 0.00) 0.01 (-0.03, 0.05) 0.00 (-0.03, 0.04) 0.00 (-0.03, 0.04) N/A
rs514708 -0.13 (-0.31, 0.05) 0.00 (-0.01, 0.01) -0.00 (-0.01, 0.00) -0.01 (-0.02, -0.00) 0.02 (-0.03, 0.06) 0.07 (0.03. 0.11) 0.03 (-0.01, 0.06) N/A
rs579459 -0.12 (-0.32, 0.07) 0.00 (-0.01, 0.01) 0.00 (-0.00, 0.01) 0.00 (-0.00, 0.01) 0.00 (-0.05, 0.05) 0.05 (0.01, 0.10) -0.05 (-0.09, -0.01) N/A
rs6984305 -0.00 (-0.25, 0.25) 0.00 (-0.01, 0.01) 0.01 (-0.00, 0.02) 0.01 (0.00, 0.02) 0.10 (0.04, 0.16) 0.07 (0.01, 0.12) -0.06 (-0.11, -0.01) N/A
rs7186908 -0.09 (-0.29, 0.12) -0.00 (-0.01, 0.01) -0.01 (-0.02, 0.00) -0.00 (-0.01, 0.01) -0.01 (-0.06, 0.04) -0.00 (-0.05, 0.04) -0.02 (-0.07, 0.02) N/A
rs7267979 0.11 (-0.05, 0.26) -0.01 (-0.01, -0.00) -0.01 (-0.02, -0.01) -0.01 (-0.02, -0.01) -0.03 (-0.07, 0.01) -0.02 (-0.05, 0.02) 0.00 (-0.03, 0.03) N/A
rs7923609 -0.01 (-0.17, 0.15) -0.01 (-0.02, -0.00) -0.01 (-0.02, -0.00) -0.02 (-0.02, -0.01) -0.00 (-0.04, 0.03) -0.02 (-0.05, 0.01) -0.00 (-0.03, 0.03) N/A
rs9467160 0.19 (0.01, 0.37) -0.01 (-0.02, -0.00) -0.01 (-0.02, -0.00) -0.00 (-0.01, 0.00) -0.03 (-0.07, 0.02) -0.04 (-0.07, 0.00) -0.00 (-0.05, 0.02) N/A
ALP 
instrument 0.02 (-0.02, 0.07) -0.00 (-0.00, -0.00) -0.00 (-0.00, -0.00) -0.00 (-0.01, -0.00) -0.00 (-0.01, 0.01) 0.00 (-0.01, 0.01) -0.00 (-0.01, 0.00) N/A
rs10513686 -0.02 (-0.26, 0.22) 0.01 (0.00, 0.02) 0.01 (-0.00, 0.02) 0.01 (-0.00, 0.02) 0.03 (-0.03, 0.08) -0.01 (-0.06, 0.04) N/A -0.01 (-0.09, 0.07)
rs1076540 0.02 (-0.17, 0.22) 0.00 (-0.01, 0.01) -0.00 (-0.01, 0.01) 0.01 (-0.00, 0.02) 0.03 (-0.01, 0.08) 0.02 (-0.02, 0.06) N/A 0.01 (-0.06, 0.07)
rs10908458 0.01 (-0.16, 0.17) 0.01 (-0.00, 0.01) -0.00 (-0.01, 0.01) -0.01 (-0.01, 0.00) 0.01 (-0.02, 0.05) 0.01 (-0.02, 0.05) N/A -0.01 (-0.06, 0.04)
rs12145922 -0.04 (-0.20, 0.12) -0.01 (-0.02, -0.00) 0.00 (-0.01, 0.01) 0.01 (-0.00, 0.01) -0.02 (-0.06, 0.01) -0.01 (-0.04, 0.02) N/A -0.01 (-0.06, 0.05)
rs1260326 -0.21 (-0.37, -0.05) -0.01 (-0.02, -0.01) -0.01 (-0.01, -0.00) 0.00 (-0.00, 0.01) 0.03 (-0.01, 0.07) 0.03 (-0.00, 0.07) N/A 0.04 (-0.01, 0.10)
rs12968116 SNP not in UCLEB 0.00 (-0.01, 0.01) 0.00 (-0.01, 0.02) 0.01 (-0.01, 0.02) SNP not in UCLEB SNP not in UCLEB N/A SNP not in UCLEB
rs13030978 -0.07 (-0.33, 0.19) -0.00 (-0.01, 0.01) -0.01 (-0.01, 0.00) -0.00 (-0.01, 0.01) 0.02 (-0.04, 0.08) 0.04 (-0.02, 0.09) N/A -0.09 (-0.17, -0.00)
rs1335645 SNP not in UCLEB 0.01 (-0.00, 0.02) 0.01 (-0.01, 0.02) 0.01 (-0.01, 0.02) SNP not in UCLEB SNP not in UCLEB N/A SNP not in UCLEB
rs1497406 0.08 (-0.12, 0.27) -0.01 (-0.01, 0.00) -0.00 (-0.01, 0.01) 0.00 (-0.01, 0.01) 0.01 (-0.03, 0.06) 0.02 (-0.02, 0.06) N/A -0.01 (-0.08, 0.05)
rs17145750 0.04 (-0.17, 0.25) -0.01 (-0.02, -0.00) -0.00 (-0.01, 0.01) 0.01 (0.00, 0.02) -0.06 (-0.11, -0.01) -0.04 (-0.09, 0.00) N/A 0.01 (-0.06, 0.08)
rs2140773 -0.08 (-0.25, 0.09) 0.00 (-0.00, 0.01) 0.00 (-0.01, 0.01) 0.01 (-0.00, 0.01) -0.00 (-0.04, 0.04) -0.02 (-0.05, 0.02) N/A -0.03 (-0.08, 0.02)
rs2739330 0.09 (-0.10, 0.28) -0.00 (-0.01, 0.01) -0.00 (-0.01, 0.00) 0.00 (-0.01, 0.01) -0.02 (-0.06, 0.03) -0.00 (-0.04, 0.04) N/A 0.04 (-0.02, 0.10)
rs339969 -0.13 (-0.31, 0.06) 0.01 (0.01, 0.02) 0.01 (-0.002, 0.02) -0.00 (-0.01, 0.01) 0.02 (-0.02, 0.06) 0.02 (-0.02, 0.06) N/A -0.01 (-0.07, 0.05)
SNP/ Age (years) BMI (SD) Waist Waist-hip ratio (SD) ALT (SD) AST (SD) GGT (SD) ALP (SD)
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ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma-glutamyl transferase; BMI: body mass index; N/A: not applicable; SD: standard 
deviation; SNPs: single nucleotide polymorphisms. GIANT: The Genetic Investigation of Anthropometric Traits. *Summary-level data publicly available from the GIANT consortium was used 
for these traits in addition to the data from the relevant UCLEB studies. 
instrument circumference (SD)
rs4074793 -0.04 (-0.34, 0.26) 0.00 (-0.01, 0.02) 0.01 (-0.01, 0.02) 0.00 (-0.01, 0.02) 0.07 (-0.00, 0.14) 0.04 (-0.03, 0.10) N/A 0.11 (0.01, 0.21)
rs4503880 SNP not in UCLEB -0.00 (-0.01, 0.01) -0.00 (-0.02, 0.01) -0.00 (-0.02, 0.01) SNP not in UCLEB SNP not in UCLEB N/A SNP not in UCLEB
rs4547811 0.12 (-0.13, 0.37) 0.00 (-0.01, 0.01) 0.00 (-0.01, 0.01) -0.00 (-0.01, 0.01) 0.06 (0.00, 0.12) 0.04 (-0.01, 0.09) N/A 0.04 (-0.04, 0.13)
rs4581712 -0.12 (-0.57, 0.32) 0.00 (-0.00, 0.01) 0.00 (-0.01, 0.01) -0.00 (-0.01, 0.01) 0.02 (-0.07, 0.11) -0.00 (-0.10, 0.09) N/A 0.03 (-0.11, 0.18)
rs4820599 -0.09 (-0.27, 0.08) -0.003 (-0.01, 0.00) -0.00 (-0.01, 0.00) -0.00 (-0.01, 0.00) -0.03 (-0.07, 0.01) -0.02 (-0.06, 0.02) N/A -0.00 (-0.06, 0.06)
rs516246 -0.16 (-0.31, -0.00) -0.01 (-0.01, -0.00) -0.01 (-0.01, 0.00) 0.01 (-0.02, 0.01) -0.00 (-0.04, 0.04) 0.00 (-0.03, 0.04) N/A -0.06 (-0.11, -0.01)
rs6888304 SNP not in UCLEB -0.01 (-0.01, 0.00) -0.01 (-0.02, 0.00) -0.01 (-0.02, 0.00) SNP not in UCLEB SNP not in UCLEB N/A SNP not in UCLEB
rs7310409 0.00 (-0.16, 0.17) 0.00 (-0.00, 0.01) 0.00 (-0.00, 0.01) 0.01 (0.00, 0.01) -0.01 (-0.04, 0.03) -0.00 (-0.03, 0.03) N/A -0.07 (-0.13, -0.02)
rs754466 SNP not in UCLEB -0.00 (-0.01, 0.01) -0.00 (-0.01, 0.05) 0.00 (-0.01, 0.01) SNP not in UCLEB SNP not in UCLEB N/A SNP not in UCLEB
rs8038465 0.11 (-0.12, 0.34) -0.00 (-0.01, 0.01) -0.01 (-0.01, 0.00) -0.00 (-0.01, 0.01) 0.06 (0.00, 0.11) 0.03 (-0.02, 0.08) N/A -0.03 (-0.11, 0.04)
rs9296736 0.09 (-0.08, 0.26) 0.01 (0.00, 0.01) 0.01 (-0.00, 0.01) 0.00 (-0.01, 0.01) 0.03 (-0.01, 0.07) -0.01 (-0.04, 0.03) N/A -0.00 (-0.06, 0.05)
rs944002 -0.24 (-0.42, -0.06) -0.00 (-0.01, 0.01) -0.00 (-0.02, 0.01) -0.00 (-0.01, 0.01) -0.01 (-0.05, 0.04) -0.01 (-0.05, 0.03) N/A -0.01 (-0.07, 0.05)
rs9913711 SNP not in UCLEB -0.00 (-0.01, 0.01) -0.01 (-0.01, 0.00) -0.01 (-0.02, 0.00) SNP not in UCLEB SNP not in UCLEB N/A SNP not in UCLEB
GGT 
instrument -0.04 (-0.08, 0.00) -0.00 (-0.00, 0.00) -0.00 (-0.00, 0.00) 0.00 (-0.00, 0.00) 0.00 (-0.00, 0.02) 0.00 (-0.00, 0.01) N/A -0.01 (-0.02, 0.00)
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Supplementary table 7b. Association of liver function markers-related SNPs with potentially confounding dichotomous traits meta-analysed across 
the relevant UCLEB studies.
Potential confounders (Odds ratio per copy of the liver function marker raising allele (95% CI))
SNP/ instrument Sex Smoking Alcohol consumption Social class
rs11597390 0.98 (0.91, 1.06) 0.97 (0.92, 1.02) 1.08 (0.98, 1.18) 1.06 (1.00, 1.14)
rs2143571 0.99 (0.89, 1.09) 1.01 (0.93, 1.09) 1.09 (0.96, 1.25) 1.08 (0.99, 1.18)
rs2954021 0.98 (0.91, 1.05) 1.03 (0.98, 1.09) 1.00 (0.92, 1.10) 1.00 (0.94, 1.06)
rs6834314 0.99 (0.92, 1.07) 0.99 (0.93, 1.05) 0.95 (0.86, 1.06) 1.01 (0.94, 1.08)
ALT instrument 0.98 (0.95, 1.02) 1.00 (0.97, 1.03) 1.02 (0.97, 1.08) 1.03 (1.00, 1.07)
rs17109512 1.09 (0.79, 1.52) 0.87 (0.68, 1.11) 1.37 (0.94, 1.99) 0.83 (0.63, 1.10)
rs738407 1.07 (0.95, 1.20) 1.00 (0.92, 1.10) 1.01 (0.87, 1.17) 1.02 (0.92, 1.13)
rs738408 1.01 (0.92, 1.12) 0.99 (0.91, 1.07) 1.03 (0.90, 1.17) 1.06 (0.97, 1.16)
AST instrument 1.04 (0.97, 1.12) 0.99 (0.93, 1.05) 1.04 (0.95, 1.14) 1.03 (0.96, 1.10)
rs10819937 SNP not in UCLEB SNP not in UCLEB SNP not in UCLEB SNP not in UCLEB
rs16856332 0.99 (0.76, 1.29) 0.95 (0.78, 1.15) 1.07 (0.78, 1.47) 1.07 (0.85, 1.33)
rs174601 1.03 (0.96, 1.11) 0.98 (0.93, 1.04) 0.95 (0.86, 1.04) 1.00 (0.94, 1.07)
rs1780324 0.97 (0.90, 1.04) 0.93 (0.88, 0.99) 0.97 (0.89, 1.07) 1.04 (0.98, 1.11)
rs2236653 0.90 (0.84, 0.98) 0.98 (0.92, 1.04) 0.95 (0.86, 1.04) 0.98 (0.91, 1.05)
rs281377 1.06 (0.99, 1.14) 0.95 (0.90, 1.00) 0.96 (0.87, 1.05) 1.04 (0.98, 1.11)
rs2954021 0.98 (0.91, 1.05) 1.03 (0.98, 1.09) 1.00 (0.92, 1.10) 1.00 (0.94, 1.06)
rs314253 0.96 (0.90, 1.04) 0.99 (0.93, 1.04) 1.04 (0.95, 1.15) 1.01 (0.94, 1.07)
rs514708 0.98 (0.90, 1.06) 0.96 (0.91, 1.02) 1.09 (0.98, 1.21) 1.03 (0.95, 1.10)
rs579459 1.01 (0.93, 1.11) 0.99 (0.92, 1.06) 1.03 (0.92, 1.15) 1.05 (0.97, 1.13)
rs6984305 1.03 (0.92, 1.16) 0.97 (0.89, 1.05) 1.04 (0.90, 1.21) 1.03 (0.93, 1.14)
rs7186908 1.05 (0.95, 1.15) 1.05 (0.98, 1.12) 1.02 (0.91, 1.15) 1.06 (0.98, 1.15)
rs7267979 1.05 (0.97, 1.12) 1.01 (0.96, 1.07) 1.01 (0.92, 1.10) 1.03 (0.96, 1.09)
rs7923609 1.00 (0.93, 1.08) 1.05 (0.99, 1.11) 1.01 (0.92, 1.11) 1.04 (0.97, 1.11)
rs9467160 0.99 (0.91, 1.07) 0.98 (0.92, 1.04) 1.01 (0.91, 1.12) 1.05 (0.98, 1.13)
ALP instrument 1.00 (0.98, 1.02) 0.99 (0.97, 1.01) 1.00 (0.98, 1.03) 1.03 (1.01, 1.05)
rs10513686 0.93 (0.84, 1.04) 0.98 (0.90, 1.06) 0.99 (0.86, 1.14) 0.99 (0.90, 1.09)
rs1076540 0.93 (0.86, 1.02) 1.02 (0.96, 1.09) 1.08 (0.97, 1.20) 0.96 (0.88, 1.03)
rs10908458 0.96 (0.89, 1.04) 0.99 (0.94, 1.05) 1.01 (0.92, 1.02) 1.02 (0.96, 1.09)
rs12145922 1.04 (0.97, 1.12) 0.95 (0.90, 1.01) 0.97 (0.89, 1.07) 1.00 (0.93, 1.06)
rs1260326 0.98 (0.91, 1.05) 0.98 (0.93, 1.04) 0.91(0.83, 1,00) 0.98 (0.92, 1.04)
rs12968116 SNP not in UCLEB SNP not in UCLEB SNP not in UCLEB SNP not in UCLEB
rs13030978 0.92 (0.82, 1.04) 1.08 (0.99, 1.19) 0.87 (0.75, 1.01) 0.94 (0.84, 1.04)
rs1335645 SNP not in UCLEB SNP not in UCLEB SNP not in UCLEB SNP not in UCLEB
rs1497406 1.04 (0.95, 1.14) 1.01 (0.94, 1.08) 0.96 (0.85, 1.07) 1.01 (0.94, 1.10)
rs17145750 1.00 (0.91, 1.10) 0.97 (0.90, 1.04) 0.89 (0.78, 1.01) 0.98 (0.90, 1.06)
rs2140773 1.05 (0.97, 1.13) 0.96 (0.91, 1.02) 1.01 (0.92, 1.11) 1.05 (0.98, 1.12)
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rs2739330 1.08 (0.99, 1.18) 1.01 (0.94, 1.07) 0.88 (0.78, 0.98) 0.98 (0.91, 1.06)
rs339969 0.97 (0.89, 1.05) 1.03 (0.96, 1.09) 0.96 (0.86, 1.07) 1.01 (0.94, 1.09)
rs4074793 0.94 (0.82, 1.09) 1.02 (0.92, 1.13) 1.02 (0.86, 1.22) 0.90 (0.80, 1.02)
rs4503880 SNP not in UCLEB SNP not in UCLEB SNP not in UCLEB SNP not in UCLEB
rs4547811 1.06 (0.94, 1.19) 0.96 (0.88, 1.05) 0.97 (0.84, 1.12) 1.03 (0.93, 1.14)
rs4581712 0.91 (0.78, 1.07) 1.02 (0.89, 1.17) 1.12 (0.88, 1.44) 0.89 (0.76, 1.05)
rs4820599 0.97 (0.89, 1.05) 1.03 (0.97, 1.09) 1.00 (0.91, 1.11) 1.01 (0.94, 1.08)
rs516246 0.95 (0.88, 1.02) 1.05 (0.99, 1.11) 1.06 (0.97, 1.16) 0.96 (0.90, 1.02)
rs6888304 SNP not in UCLEB SNP not in UCLEB SNP not in UCLEB SNP not in UCLEB
rs7310409 0.97 (0.90, 1.04) 0.97 (0.92, 1.03) 1.04 (0.95, 1.14) 1.05 (0.98, 1.12)
rs754466 SNP not in UCLEB SNP not in UCLEB SNP not in UCLEB SNP not in UCLEB
rs8038465 0.97 (0.88, 1.08) 1.02 (0.94, 1.10) 1.08 (0.95, 1.24) 1.03 (0.93, 1.13)
rs9296736 1.04 (0.96, 1.13) 0.98 (0.92, 1.04) 0.95 (0.86, 1.04) 1.05 (0.98, 1.12)
rs944002 0.98 (0.90, 1.07) 1.05 (0.99, 1.12) 1.04 (0.94, 1.16) 1.00 (0.93, 1.08)
rs9913711 SNP not in UCLEB SNP not in UCLEB SNP not in UCLEB SNP not in UCLEB
GGT instrument 0.99 (0.97, 1.01) 1.00 (0.99, 1.02) 0.99 (0.96, 1.01) 1.00 (0.98, 1.02)
ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma-glutamyl transferase; SNPs: single nucleotide polymorphisms; 
UCLEB consortium: UCL-LSHTM-Edinburgh-Bristol consortium 
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Supplementary table 8. Fully adjusted multivariable regression and Mendelian Randomization associations / effects of liver function markers 
with continuous outcomes meta-analysed across UCLEB, Fenland* and GWAS studies
 Mean difference (in S.D units) for each continuous outcome per one S.D increase in each liver function marker (95% CI)
Glucose Insulin HDL-C LDL-C Total cholesterol Triglycerides
(mmol/L) (μIU/ml) (mmol/L) (mmol/L) (mmol/L) (mmol/L)
ALT
Multivariable 0.08 (-0.03, 0.19) 0.19 (0.11, 0.28) -0.01 (-0.04, 0.02) 0.03 (-0.03, 0.08) 0.06 (0, 0.11) 0.1 (0.05, 0.15)
MR-IVW -0.01 (-0.09, 0.07) -0.01 (-0.09, 0.06) -0.09 (-0.35, 0.16) 0.08 (-0.33, 0.48) 0.05 (-0.39, 0.48) 0.07 (-0.45, 0.59)
MR-Egger 0.12 (-0.11, 0.34) 0.08 (-0.13, 0.29) 0.62 (0.16, 1.09) -0.75 (-1.54, 0.04) -0.8 (-1.7, 0.11) -1.07 (-2.16, 0.02)
MR-Weighted median -0.02 (-0.17, 0.12) 0 (-0.08, 0.08) -0.09 (-0.25, 0.07) -0.1 (-0.2, 0.01) -0.11 (-0.21, -0.01) -0.06 (-0.16, 0.04)
AST
Multivariable 0 (-0.04, 0.04) 0.05 (0.01, 0.09) 0.06 (0.04, 0.09) -0.02 (-0.05, 0.01) 0.01 (-0.02, 0.03) 0.02 (-0.04, 0.07)
MR-IVW -0.01 (-0.07, 0.04) 0.01 (-0.04, 0.06) -0.09 (-0.15, -0.04) -0.07 (-0.13, -0.01) -0.11 (-0.17, -0.04) 0.03 (-0.03, 0.08)
MR-Egger 0.01 (-0.18, 0.2) 0.08 (-0.03, 0.18) -0.06 (-0.19, 0.07) -0.17 (-0.31, -0.02) -0.21 (-0.34, -0.07) -0.03 (-0.16, 0.09)
MR-Weighted median -0.01 (-0.06, 0.04) 0.01 (-0.04, 0.06) -0.09 (-0.15, -0.03) -0.07 (-0.13, -0.01) -0.11 (-0.17, -0.04) 0.02 (-0.03, 0.08)
ALP
Multivariable 0.01 (-0.04, 0.06) 0.02 (-0.03, 0.08) -0.04 (-0.08, -0.01) 0.02 (-0.04, 0.07) 0.02 (-0.04, 0.07) 0.05 (0, 0.1)
MR-IVW -0.03 (-0.08, 0.03) -0.01 (-0.04, 0.01) -0.06 (-0.13, 0.02) -0.17 (-0.28, -0.06) -0.16 (-0.28, -0.04) 0.08 (-0.07, 0.24)
MR-Egger -0.06 (-0.22, 0.1) 0 (-0.05, 0.04) -0.07 (-0.35, 0.21) -0.27 (-0.46, -0.07) -0.25 (-0.45, -0.05) 0.03 (-0.28, 0.34)
MR-Weighted median -0.03 (-0.06, 0) -0.01 (-0.04, 0.02) -0.03 (-0.12, 0.06) -0.2 (-0.34, -0.06) -0.19 (-0.31, -0.08) 0.03 (-0.05, 0.12)
GGT
Multivariable 0.07 (0.02, 0.11) 0.1 (0.04, 0.16) 0.04 (0.01, 0.07) 0.05 (0, 0.1) 0.11 (0.06, 0.16) 0.15 (0.1, 0.2)
MR-IVW -0.05 (-0.12, 0.03) -0.02 (-0.07, 0.02) -0.04 (-0.08, 0) -0.03 (-0.1, 0.03) 0.02 (-0.07, 0.11) 0.16 (0.02, 0.3)
MR-Egger 0.07 (-0.11, 0.24) 0.1 (-0.01, 0.22) -0.07 (-0.17, 0.03) -0.11 (-0.38, 0.16) -0.17 (-0.37, 0.02) -0.14 (-0.44, 0.17)
MR-Weighted median 0 (-0.11, 0.11) -0.01 (-0.05, 0.03) -0.03 (-0.07, 0.01) -0.06 (-0.15, 0.03) -0.04 (-0.11, 0.04) 0 (-0.04, 0.04)
*Fenland study was only included in the instrumental variables analyses of the associations between the exposures ALT, ALP, GGT and lipid outcomes. IVW: inverse-variance weighted method. 
ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma-glutamyl transferase; UCLEB consortium: UCL-LSHTM-Edinburgh-Bristol 
consortium; GWAS: Genome-wide association study; MR: Mendelian randomization; IVW: Inverse variance weighted estimator; S.D: standard deviation; HDL-C: high density lipoprotein-
cholesterol; LDL-C: low density lipoprotein-cholesterol
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Supplementary table 9. MR-Egger intercept values (pooled across UCLEB, Fenland and GWAS studies)
Mean difference (S.D) of each continuous outcome per one S.D increase in the liver function marker (95% CI)
Liver function 
marker Glucose
(mmol/L)
Insulin
(μIU/ml)
HDL-C
(mmol/L)
LDL-C
(mmol/L)
Total cholesterol
(mmol/L)
Triglycerides
(mmol/L)
ALT 
MR-Egger intercept -0.01 (-0.02, 0.01) 0 (-0.01, 0.01) -0.04 (-0.06, -0.01) 0.05 (0.02, 0.09) 0.06 (0.02, 0.1) 0.06 (0.01, 0.12)
AST 
MR-Egger intercept 0.03 (-0.01, 0.07) 0.01 (-0.02, 0.04) 0 (-0.02, 0.03) 0.01 (-0.05, 0.07) 0.01 (-0.06, 0.08) 0.01 (-0.02, 0.03)
ALP 
MR-Egger intercept 0.01 (-0.01, 0.02) 0 (-0.01, 0.01) 0 (-0.03, 0.02) 0.01 (-0.01, 0.02) 0.01 (-0.01, 0.02) 0.01 (-0.01, 0.02)
GGT 
MR-Egger intercept -0.01 (-0.03, 0) -0.01 (-0.02, 0) 0 (-0.01, 0.01) 0.01 (-0.02, 0.03) 0.01 (0, 0.03) 0.02 (0, 0.04)
ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma-glutamyl transferase; HDL-C: high density lipoprotein-cholesterol; LDL-C: low 
density lipoprotein-cholesterol; UCLEB consortium: UCL-LSHTM-Edinburgh-Bristol consortium; GWAS: Genome-wide association study; MR: Mendelian randomization; IVW: Inverse variance 
weighted estimator; S.D: standard deviation.
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